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Metabolic Reprogramming of Pancreatic Ductal 
Adenocarcinoma Cells In Response To Chronic Low pH Stress 
 
Jaime Abrego, Ph.D. 
 
University of Nebraska Medical Center, 2017 
 
Supervisor: Pankaj K. Singh, Ph.D. 
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal of all 
cancers with a 5-year survival rate of only 8.2%. This is because PDAC is diagnosed in 
its advanced stages and is characterized by radio and chemotherapy resistance. 
Aggressiveness of PDAC tumors is attributed to its high metabolic phenotype, which is 
characterized by increased glycolysis rate and lactate secretion, while oxidative 
metabolism is reduced. These metabolic features are required to fulfill the biosynthetic 
demands of proliferating PDAC cells. However, this increase in metabolic activity results 
in acidification of the extracellular space because the dense fibrotic stroma of PDAC 
tumors limits venting of protons into the vasculature thereby creating a chronic low pH 
microenvironment. Little is known regarding the physiology and metabolism of cancer 
cells enduring chronic low pH exposure.  
To demonstrate effects of low pH, PDAC cells were cultured in low pH 6.9~7.0 to 
establish chronic low pH as it occurs in tumors. These cells were compared to cells in 
physiological pH of 7.4, which is also the pH of cell culture, in order to evaluate 
physiological differences between these pH values.  In these experiments, it was 
observed that cells in low pH have reduced clonogenic capacity and undergo a 
metabolic shift to oxidative metabolism that is supported by an increase in glutamine 
uptake. These observations exhibit a robust contrast to PDAC cells in control pH 
conditions that are highly glycolytic. Furthermore, in low pH there is increased 
	 vi	
transcription of the GOT1 enzyme, which mediates metabolic flux through the non-
canonical glutamine metabolic pathway that allows synthesis of other metabolic 
substrates from glutamine. Upon shRNA-mediated depletion of GOT1, survival of PDAC 
cells in low pH was significantly impaired due to increase in ROS to cytotoxic levels. 
However, supplementing transfected clones with GOT1 metabolic product, oxaloacetate, 
resulted in growth rescue and reduction in ROS levels. Thus, in chronic low pH stress 
PDAC cells up-regulate non-canonical glutamine metabolism through increased 
transcription of GOT1, which allows PDAC cells to generate energy and metabolic co-
factors to suppress cytotoxic ROS levels. Low pH is a universal feature of the PDAC 
tumor microenvironment and further dissection of metabolic adaptations to 
microenvironment conditions will result in more effective therapy for PDAC. 
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Chapter 1 
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Tumor Microenvironment  
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Incidence of Pancreatic Ductal Adenocarcinoma 
According to the American Cancer society, the estimate of new cases of 
pancreatic cancer in 2017 is 53,670 and the number of estimated deaths is 43,090 [1, 2]. 
Needless to say, the 5-year survival rate is also very low at 8.2%, figure 1 [1, 2]. These 
grim statistics have remained virtually unchanged over the past two decades. For this 
reason, a diagnosis of pancreatic ductal adenocarcinoma (PDAC), the most common 
type of pancreatic cancer representing 90% of all pancreatic cancers, is synonymous of 
a death sentence as it carries one of the most dismal prognoses in all of medicine [3]. 
Poor disease outcome can be attributed to the lack of specific symptoms and limitation 
in diagnostic methods allowing PDAC to elude detection during its formative stages; as a 
result, PDAC is typically diagnosed in its advanced stages [4]. Currently, the only 
reasonable hope of cure is through surgical resection, which in itself is a life-threatening 
procedure, but rarely a curative end point is achieved due to disease spread and 
recurrence [5]. Non-invasive procedures include radiation therapy and chemotherapy; 
however, improvement of long-term survival is minimal due to pronounced PDAC 
therapy resistance [6]. Thus, most treatments are palliative with the goal of improving the 
quality of life in patients [6]. Alarmingly, the incidence of PDAC is expected to double 
within the next 15 years [6]. For this reason, there is desperate need to understand the 
complex biology of PDAC carcinogenesis in order to identify more effective therapeutic 
approaches and improve patient survival. 
Development of Pancreatic Ductal Adenocarcinoma 
Acquisition of Oncogenic Mutations 
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A basic tenet of Natural Selection is the constant occurrence of purposeless 
mutations that increase genetic variability on which selection forces act. For a mutation 
to occur, a complete cell division cycle must take place. Human DNA polymerases have 
an error at a rate of 1x10-9 per base on each replication round [7-9]. Therefore, 
statistically speaking, three single nucleotide variants occur per replication cycle of 
somatic cells. Considering the human haploid genome is 3x109 base pairs 
long and that the number of cells in an adult body is approximately 1014, mutations are 
likely to occur at any time [8]. However, mathematical models predict that the 
emergence of new strategies (phenotypes) in individual cells during tissue turnover does 
not improve fitness and cancer requires more steps [10, 11]. Furthermore, not all cells in 
the body are actively replicating this includes acinar and ductal cells of the adult 
pancreas where PDAC originates [12, 13]. Thus, by simple chance alone, the incidence 
of PDAC is rare, but if PDAC is to develop the initial mutation must be fixed to the 
normal tissue landscape in order to hide from pathologic response such as tissue growth 
constraints and immune responses that would lead to senescence and/or apoptosis. 
This will allow the pre-malignant phenotype to proliferate giving more opportunities for its 
clones to gain additional genomic instability that will lead to cancer, i.e. PDAC 
signature. Perhaps, this explains the time frame between initial mutation, which occurs 
at minimum two decades, and PDAC diagnosis [13]. The median age for diagnosis 
of PDAC is 71 and 75% of cases are diagnosed between the ages of 55 and 84 [2, 3, 
13].  Recent statistical analyses of various cancer types, including PDAC, calculated 
high risk due to a strong correlation with aging and the predicted number of normal stem 
cell divisions [14, 15]. However, there is much debate to describe links for PDAC 
induction due to intrinsic factors, carcinogens, and non-cancerous pathophysiology of 
cancer. 
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Intrinsic factors occur because of chance events such as failure in genetic 
replication, but this event is very unlikely in healthy patients. The most common intrinsic 
factors that increase PDAC risk are familial traits where gene variants involved in DNA 
double-strand break repair such as BRCA1, BRCA2, PALB2, FANCC, FANCG, and 
ATM [16]. Understandably, defective DNA repair mechanism would increase genetic 
instability and chances for somatic mutations to occur.  Familial variants affecting tumor 
suppressors also have robust incidence with PDAC. For example, germline mutations to 
CDKN2A that encodes two proteins that regulate cell cycle progression these are 
p16INK4A and p19ARF [16]. Carcinogens that damage the genome or alter metabolic 
functions, as well as, tissue inflammation, cell turnover due to idiopathic diseases, and 
organ specific disease all account for extrinsic factors of high PDAC risk [17]. It has been 
demonstrated extensively that continuous exposure to pro-
inflammatory agents increases ROS levels that promote DNA damage [18]. Inflammation 
of the pancreas, also known as pancreatitis, caused by alcohol abuse and 
smoking is associated high PDAC risk [19, 20]. Similarly, patients diagnosed with PDAC 
are often diagnosed with diabetes type II (hyperinsulemia) and are classified as obese; 
both of these conditions are associated with chronic inflammation of the pancreas [21]. 
Although it is unclear the mechanism of cooperation between genomic alterations and 
tissue damage, both of these cause initial events leading to PDAC. In the context of 
PDAC evolution, it is likely that the initial mutation occurs randomly, becomes fixed to 
tissue landscape, and awaits for tissue damage to induce other genomic alterations and 
evolve to PDAC [10, 14]. Thus, one could argue that the initial mutation is caused 
intrinsically or by exposure to carcinogens and life style choices such as diet and alcohol 
abuse will increase pancreatic burden paving the way for somatic evolution of PDAC. 
Therefore, healthy status and normal function of the pancreas is critical in holding back 
PDAC. Table 1A and Table 1B highlight intrinsic and extrinsic PDAC risk factors. 
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Pancreatic Ductal Cell Function 
The pancreas is a glandular organ of the digestive and endocrine systems 
located in the abdominal cavity behind the stomach [22]. The histological features of the 
pancreas are easily distinguishable under the microscope. Pancreas tissue with 
endocrine role is arranged in clusters called pancreatic islets and constitutes about 1 to 
2% of the total pancreas volume [22]. The critical metabolic hormones for metabolic 
response, insulin and glucagon, are produced by beta and alpha cells, respectively, in 
pancreatic islets [5]. The rest of the pancreas functions as part of the exocrine digestive 
system composed of exocrine and ductal epithelium [22]. Acinar exocrine cells of the 
pancreas, form clusters called acini, for the berry-like sac architecture [5]. This hollow 
structure formed by acinar cells converges with epithelial cells of the pancreas to form a 
ductal system designed for the delivery of digestive enzymes to the duodenum [5, 22]. 
The enzymes secreted by acini are lipase, proteases, and nucleases; while the ductal 
cells secrete large amounts of sodium bicarbonate (NaHCO3) [22, 23].  
Pancreatic cancers develop 95% of the time from exocrine cells and most 
commonly from ductal cells 85-95% (PDAC), while cancer from acinar cells and 
endocrine both represent less than 5% [22]. This is likely because more progenitor cells 
are needed to replace the dispensable epithelial cells lining the pancreatic ducts 
because ductal epithelium is exposed to more stress and thus progenitor cells undergo 
more replication cycles increasing the chance for acquiring mutations. Some ambiguity 
in PDAC origin exists because acinar cells are known to undergo acinar-ductal 
metaplasia in pre-malignant lesions through increased expression of KRAS and 
pancreatic progenitor cell transcription factors SOX9 and PDX1 [24]. Interestingly, 
pancreatic cancers of exocrine origin are much more aggressive than pancreatic 
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endocrine [25]. Thus, the function of pancreas exocrine and its condition in pathologic 
circumstances must be addressed to learn more about PDAC initiation.   
In normal conditions the pancreatic ductal cells secrete up to 140mM of sodium 
bicarbonate, which is useful to neutralize the acid chime that enters the duodenum [23]. 
Interesting research on inhibition of bicarbonate release by ductal cells shows to be 
reduced upon enzyme release by acinar cells while acinar secretion of chloride and ATP 
has been demonstrated to stimulate ductal bicarbonate secretion [23]. Furthermore, 
recent findings show that acinar exocytosis causes a significant acid load into the ductal 
cavity thereby decreasing the pH by up to 1 unit [26]. Normally the pH in duct fluid is 8, 
figure 2 [26]. Therefore, pH control by ductal cells is critical for tissue homeostasis, as 
decease in pH has been shown to induce inflammation [23]. This has been 
demonstrated in animal models where induction of pancreatitis by cerulein treatment 
lowers the pH of ductal fluid [23, 27]. Similar findings have been noticed in drug 
treatments, acid injections to the pancreas in experimental pancreatitis mouse models, 
and in mutations affecting mitochondrial function that cause lactic acidosis [28]. 
Interestingly, ethanol exposure has been shown to decrease blood flow to the pancreas 
by up to 60% causing hypoxic response and drop in pancreatic tissue extracellular pH 
(pHe) to 7.1 [29]. This study highlights the role of the pancreatic ductal cells in blood pH 
homeostasis by removing CO2 (metabolic acid) and converting it to bicarbonate that is 
then used to regulate the pH of ductal fluid. Furthermore, idiopathic diseases affecting 
blood flow may damage the pancreas indirectly by altering pH dynamics. Interestingly, 
approximately 75% of PDAC tumors occur in the head of the pancreas where it links to 
the duodenum. Therefore, bicarbonate secretion from ductal cells is critical to buffer the 
pH from stomach acids and acinar secretions. These observations show how critical 
bicarbonate secretions from ductal cells are for pH regulation for normal exocrine tissue 
	 7	
function, as lowering of the pH increases risk of pancreatitis, which in turn increases risk 
for PDAC greatly [30].    
Pancreatic Ductal Adenocarcinoma as an Evolutionary Process 
Solid tumors, such as PDAC, appear to progress in a stepwise manner. The first 
step is acquisition of driving mutations, followed by clonal expansion from an initial 
malignant cell, and third is local invasion and metastasis. Intriguingly enough, 
progression of PDAC drastically affects the physical features of its tumor 
microenvironment (TME) characterized by hypoxia, acidosis, and high interstitial 
pressure [31]. However, the harsh conditions in the TME do not appear to oppose 
carcinogenesis, instead, it seems to promote fitness of the tumor cells promoting 
acquisition of phenotypes that promote cancer aggressiveness. Throughout this 
introductory chapter, I will address carcinogenesis of PDAC as if it were a process 
subjected to Darwinian evolutionary processes with the goal of instigating novel insights 
and opportunities for study. 
The model of Natural Selection, as proposed by Charles Darwin, is simply 
defined by the differential rates of survival and reproduction due to differences in 
phenotype of competing species [32]. These rules impose that the carrier of the fittest 
phenotype will get to survive, reproduce, and pass on the given trait to offspring. The 
process of evolution can be categorized by the strategy of adaptability (phenotype) and 
predictable outcomes allowing us to mathematically model evolution of species 
populations with the given resources of an ecosystem [32]. Adaptations of these 
mathematical methods have been used to determine the evolutionary potential of cancer 
cells [10, 33]. These mathematical models utilize two broad control mechanisms of 
multicellular organisms, which are tissue development regulators and substrate 
availability [10, 33, 34]. The former consists of complex growth control mechanisms such 
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as: cell-cell and cell-ECM (extracellular matrix) interactions, as well as, response to 
soluble growth factors [35]. Glucose is the universal substrate in catabolic metabolic 
reactions; thus tissue uptake capacity and basal metabolic uptake can be calculated 
based on extant literature [10, 33]. 
Mathematical analysis of normal epithelial tissue dynamics reveals that 
populations of normal cells have decreased fitness upon reaching tissue equilibrium [10]. 
Furthermore, evolutionary models show that loss of fitness is independent of growth 
strategy (phenotype), which means that tissue stability is due to cooperation of co-
existing non-competing populations, if more than one population with different survival 
strategy were to exist within the same tissue [10, 33]. Therefore, each individual cell in 
epithelial tissue gives away its individual growth potential for normal tissue development 
and the overall good of the whole organism. This also implies that initial oncogenic 
mutations will not cause cancer alone, but will rather be fixed into the tissue landscape. 
Subsequent evolution of cancer is elicited by environmental factors such as 
inflammation, which will cause clonal expansion of pre-cancerous tissue-fixed cells 
giving room for acquisition of somatic mutations to further enhance fitness of mutant 
cells causing a relaxation in growth regulation trough contact inhibition by disrupting to 
cell-cell or cell-basement membrane interactions [35]. Further adaptations promoting the 
cancer phenotype are induced by micro-environmental changes such as hypoxia and/or 
lack of nutrients since cell population growth leads to separation from blood vessels [36]. 
Thus, mathematical simulation models of cancer evolution are possible if the factors of 
dynamic progression of cancer are provided through experimental observation [10, 33, 
34]. Based on mathematical modeling and experimental observations the evolutionary 
model of carcinogenesis has 3 defined stages of cancer: initiation, promotion, and 
progression, figure 3. 
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PDAC carcinogenesis fits an evolutionary model of cancer progression since its 
genetic signature is well characterized (KRAS, CDKN2A, TP53, SMAD4), as well as, 
characteristics of its TME (hypoxia, acidosis, high interstitial pressure) and survival 
outcome (activation of Warburg effect metabolism, fibroblast activation, immune 
evasion) [5, 36, 37]. Thus, in its formative stages PDAC is limited by tissue growth 
constraints (extrinsic factors), but once the oncogenic phenotype arises further survival 
is defined by cellular homeostasis and the metabolic adaptations required to sustain it. In 
the following sections I will address how pancreatic epithelial cells become oncogenic to 
develop PDAC. 
Neoplastic evolution of PDAC 
The evolution of malignant cell into PDAC requires several steps that have been 
histologically characterized by observable pancreatic lesions, also known as pancreatic 
intraepithelial neoplasms (PanINs). The normal pancreatic ductal epithelium houses low-
cuboidal cells lining ducts in a single layer and nuclear atypia is not seen [38]. PanIN-1, 
is characterized by increased mucin secretion, cell elongation, and observable papillary 
architecture. PanIN-2, is characterized by nuclear abnormalities such as: nuclear 
crowding, hyperchromatism, and enlarged nuclei, as well as, some loss of polarity [38]. 
Cells budding into the lumen, nuclear atypia, and increased mitosis 
characterize PanIN stage 3 [38]. PDAC diagnosis follows PanIN-3, as it is characterized 
by invasive growth and marked desmoplasia [38]. PDAC tumors show an increased 
frequency of mutations in KRAS, CDKN2A, TP53, and SMAD4 with increasing PanIN 
staging [14].  
Substantial evidence in PanINs suggests PDAC occurs in a linear progression. 
Mutant KRAS is expressed in 99% of PanIN-1 and its proportionality increases in high-
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grade pancreatic lesions [38]. This indicates fixation of oncogenic KRAS in normal 
pancreatic epithelium and its selection in pancreatic lesions. Loss of p16INK4A is known to 
occur most often during PanIN-2 and it shows increased loss in PanIN-3 [38]. Loss of 
TP53 and SMAD4 is known to occur in PanIN-3 lesions and invasive PDAC [38]. The 
accumulation of these classic features of the PDAC genetic landscape show a pattern of 
progression that seems to require progressive fixation of these mutations as if these 
alterations are requirements in evolution of somatic cell to PDAC, i.e. 
KRASàCDKN2AàTP53àSMAD4. In the following sections, I will address more 
specifically the stepwise progression of PDAC. 
1. KRAS  
KRAS is a member of the RAS family of small-protein GTPases, whose enzyme 
function is to hydrolize GTP into GDP and acts as a signal transducer when active in the 
GTP conformation, figure 4 [39, 40]. In normal cells KRAS is activated by extracellular 
growth factors and consequent growth-factor receptor activation. Active KRAS is an 
important molecule in a plethora of signal transduction pathways, figure 4 [39, 40]. For 
this reason it is instrumental in cell to growth, proliferation, as well as, maturation of cells 
to take on specialized functions (differentiation) [39, 40]. Wild-type KRAS is regulated by 
guanine exchange factor proteins (GEFs) whose function is to turn off/on by exchanging 
GDP for GTP [39, 40]. Therefore, KRAS function is regulated by growth factors, GEFs, 
and GTP/GDP ratio. Most mutations in the KRAS gene are believed inhibit GTP 
hydrolysis thereby becoming constitutively active [39, 40]. KRAS is located on the short 
arm of chromosome 12, and it suffers mutations in codons G12, G13, and Q61 with the 
most common amino acid substitutions being G12D, G12V, G13D, and Q61H [39, 40]. 
Oncogenic KRAS expression is nearly ubiquitous in PDAC carcinogenesis with ~99% 
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expression in PanINs and 95% in tumors [38]. Oncogenic KRAS provides fitness to 
malignant cells because it mediates uncontrolled proliferation.  
Several studies have demonstrated that autocrine epithelial growth factor (EGF) 
signaling occurs in low-grade PanINs due to overexpression of EGF-family ligand 
receptors EGFR and ERBB2 [5, 40, 41]. Similarly, EGF signaling results in stimulation of 
the phosphatidylinositol-3-kinase (PI3K) pathways [41]. Activated KRAS can itself 
interact with and activate PI3K [40]. PI3K acts on downstream effectors AKT and mTOR 
(PI3K/AKT/mTOR transduction signaling pathway) and activates metabolic pathways 
that enhance the cellular rate of macromolecule biosynthesis by increasing membrane 
expression of nutrient transporters and glycolysis genes [41]. More specifically, AKT 
stimulates lipid synthesis, while mTOR regulates protein translation [41]. Hypothetically, 
acute damage to pancreatic epithelium will lead to increase in EGFR in response to 
injury and to promote tissue regeneration. However, if a cell bearing oncogenic KRAS 
has been fixed into the pancreatic tissue, increased cell turn over caused by tissue 
damage will stimulate both EGFR-dependent activation of PI3K/AKT/mTOR pathway 
and oncogenic-KRAS. In this scenario the mutant cells may expand because of growth 
factor independency. However, cell division is restrained by cell-cell, cell-basement 
membrane interactions, and growth cycle checkpoint inhibition [17]. Maintenance of 
oncogenic KRAS is central for continued uncontrolled growth and increased metabolic 
rate in advanced disease. 
2. CDKN2A 
The second genomic alteration in the PDAC stepwise progression is the loss of 
tumor suppressor CDKN2A, which encodes for genes p16INK4A and p19ARF because of a 
shared locus on chromosome 9p [42]. These genes are differentially regulated because 
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of different reading frames on their first exon [43]. Interestingly, the CDKN2A locus is 
inactivated 90% of the time in PDAC and evidence from mouse models and human data 
suggests mutations are targeted for p16INK4A [44]. However, larger alterations to 
CDKN2A locus will result in loss of both p16INK4A and p16ARF in an event that can 
contribute to PDAC through different mechanisms [43]. p16INK4A plays an important role 
in cell cycle regulation by inhibiting cyclin-dependent kinases CDK2 and CDK4 
(cyclinD/CDK2,4 complex), which phosphorylate retinoblastoma protein (pRB) causing 
its disassociation from E2 Factor (E2F) thereby allowing it to begin transcription of 
cylcinA and cyclinE [45]. These last two may interact with CDK2 (CyclinA, E/CDK2 
complex) inducing passage through G1/S-checkpoint of cell cycle, figure 5 [45]. Loss of 
CDKN2A gene is commonly seen in medium-grade pancreatic lesions, PanIN-2 [5, 38]. 
Therefore, this adaptation is likely to favor established oncogenic KRAS mutants by 
allowing the biosynthetic machinery to make more DNA. Furthermore, induction of 
CDKN2A increases during environmental stress to suppress mitogenic stimulation [45]. 
The KRAS-CDKN2A mutations promote DNA synthesis that leads to the genomic 
instability seen in PanIN2, which may cause DNA sequence errors and/or shortening of 
telomeres to occur forcing activation of TP53 gene to transcribe p53 DNA damage 
response genes and cause senescence or apoptosis. Thus, the genetic alterations in 
KRAS and CDKN2A/p16 are likely to cause extensive genomic alterations forcing 
adaptation to suppress DNA damage response, anti-proliferative, and anti-senescence 
mechanisms all of which may be regulated by p53. 
3. TP53 
The tumor protein 53 (TP53), or p53, is a transcription factor whose function is 
stimulated in response to DNA damage or stress. p53 activation in normal cells leads to 
growth arrest or apoptosis to maintain genome integrity; hence, its proclamation as 
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guardian of the genome [46]. TP53 is somatically mutated, approximately, in 85% of all 
PDACs, with nearly 66% of mutations targeting its DNA binding domain [38]. The role of 
p53 in protecting genome integrity of pancreatic cells in preventing PDAC, as 
demonstrated by familial PDAC that is induced by is loss of gene ataxia telangiectasia 
mutation (ATM) whose function in cells is to relay stress signals to p53; loss of p53 
signaling axis leads to high risk and induction of PDAC [47]. Dysfunctional p53 would not 
conduct G1/S and G2/M checkpoints or respond to telomere shortening [46]. Thus, 
absence of p53 response to genomic damage will result in uncontrolled proliferation. 
Mutations in TP53 gene correlate with significant features of dysplasia in PanIN-3 [38]. 
Absence of p53 improves fitness of cells bearing oncogenic KRAS and CDKN2A, as the 
removal of mitosis breaks will result in clonal expansion leading to loss of polarity 
diminishing growth constraints due to cell-cell and cell-basal membrane interactions. 
Furthermore, increased rate of mutations will likely select for a new genotype capable to 
survive in emerging microenvironment stress factors. Figure 6 highlights the p53 
response in normal cells.  
4. SMAD4 
SMAD4 function is lost in approximately 55% of PDACs and contributes to PDAC 
progression due to inactivation of TGFβ-mediated growth inhibition, which blocks G1/S 
cell cycle transition [38, 48]. Interestingly, the TGFβ pathway plays an inhibitory role in 
PanIN-1 and PanIN-2, but supports progression to PDAC in PanIN-3 role possibly 
because it promotes paracrine signaling leading to activation of pancreatic stellate cells 
(PSCs) that cause tissue desmoplasia [49]. Indeed, loss of SMAD4 shows the 
predisposition of PDAC to form a strong desmoplastic reaction because familial loss of 
SMAD4 does not predispose to PDAC [50]. However, if familial SMAD4 mutation is 
concomitant with PDAC, the cancer is more aggressive and highly fibrotic [50]. Deletion 
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of SMAD4 is a late event in PanIn3 progression to PDAC and is likely a progression 
allele in PDAC. Nevertheless, loss of function of SMAD4 decreases ability to restrict 
unrestricted proliferation and as a result it would lead to increase in fitness of PDAC 
cells.  
Features of Pancreatic Ductal Adenocarcinoma 
Genetic expression analyses of PDAC progression in human samples suggests 
progression of PanIN-1 to PDAC takes approximately 12 years [51]. The time between 
PanIN lesions and PDAC is not well defined. However, experimental evidence suggests 
a 3-step process clonal transformation, clonal expansion, and invasion. First ductal cells 
require an oncogenic mutation (KRAS) (transformation), second the mutant cells need to 
become the dominant phenotype in the tissue (clonal expansion), and lastly intrinsic 
mechanisms of tumor suppression need be removed through loss of tumor suppressor 
function (CDKN2A and TP53) (invasion). Movement of the transformed cell population 
from the pancreatic ducts into the ductal lumen and developing a stroma characterized 
by increased desmoplasia and further clonal expansion; these are the histological 
features of PDAC [38]. Stochastic growth follows initial spread of malignant cells into the 
pancreas, as the cancer population faces growth and environmental challenges [52]. 
Further progression of cancer is not immediate as evidenced in genetic expression 
analyses suggesting progression form early PDAC to metastatic PDAC takes nearly 7 
years, possibly because of tissue instability and immune response. During this time, 
PDAC cells generate a dynamic and complex TME characterized by infiltration of various 
cell types, extensive extracellular matrix (ECM), as well as, restricted nutrient and 
oxygen availability [37]. Thus, the TME of the PDAC tumor imposes potent selection 
forces to shape ongoing adaptation and promote clonal expansion of initial populating 
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cells, which in turn will increase cellular heterogeneity of cancer cell population. Fitness 
of cancer cells must be enhanced trough genetic, epigenetic and phenotypic alterations 
in order to outcompete the host. 
The time elapsed between gain of metastatic potential and the time of death is 
predicted to be nearly 3 years [51]. PDAC diagnoses are assigned four stages: stage 0 
(non-invasive), stage 1 (invasion throughout pancreas), stage 2 (lymphatic invasion), 
stage 3 (invasion to nerves and blood vessels), and stage 4 (metastatic) [3]. Alarmingly, 
nearly 80% of all cases are found to be invasive with 50% of these bearing metastatic 
sites [2, 3]. It has been observed that metastasis is an early event in PDAC [53]; thus, 
tumors do not follow this staged linear progression to metastasize. It is more likely that a 
random wave of alterations improve fitness of cells in primary site giving rise to cells with 
metastatic potential. Indeed, genetic expression analyses indicate tumor heterogeneity 
derives autonomous and non-autonomous cell population. In terms of tumor evolution 
this means that cancer cells in the primary tumor site must become fixated to the tumor 
tissue landscape. Once a landscape threshold is reached, cancer cells will be obligated 
to undergo further selection to gain autonomy from primary tumor constraints the result 
is gaining the ability to metastasize. Similarly, the same selection process is likely to 
induce formation of cancer stem cells, which is another survival strategy. This notion is 
supported through several lines of evidence such as the fact that 99% of metastatic 
attempts fail as cells cannot survive more than 24 hours [54]. There is also no genetic 
signature for metastases, but metastasis is favored by acquisition of pre-malignant 
mutations (KRAS, CDKN2A, TP53, and SMAD4) [55]. Lastly, mathematical models also 
agree that adaptation to microenvironment before metastasis requires 5-10 years [51]. 
Figure 7 highlights the progression of PDAC. 
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PDAC cancer cells exponentially increase substrate uptake, as demonstrated by 
[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging of human 
tumors, which shows significantly increased glucose uptake of tumors compared to 
normal adjacent tissue [36, 56]. The metabolic shift to increase aerobic glycolysis and 
limitation of mitochondrial oxidative phosphorylation, also known as the Warburg effect, 
is a universal feature of solid tumors since increase in glucose uptake is up to 1000 
times more than normal cells [34, 36, 56]. Thus, FDG-PET scans are conducted to 
diagnose PDAC and for evaluation of therapy response of primary site and metastases. 
This behavior of cancer cells is logical because cells need biomass to proliferate to 
achieve this metabolic output is maximized [36]. A caveat of increased metabolism is 
excess production of metabolic acids. Interestingly, cancer cells exhibit a unique pH 
gradient in which the internal pH (pHi) is alkaline raging from pH 7.3-7.6 and an acidic 
extracellular pH ranging from pH 6.5-7.0. Experimental evidence shows that an alkaline 
pHi enhances metabolic rate, but decreased in pHi limits proliferation and survival of 
cancer cells [57]. In evolutionary terms, this means that survival/fixation of cancer cells in 
primary tumor landscape and further progression exclusively depends on pH regulation. 
In the following sections I will address the emergence of altered metabolism in PDAC 
and evolution to dysregulated pH dynamics because of Warburg effect metabolism. 
Desmoplasia a Hallmark of PDAC 
The response to heal tissue damage in the pancreas is particularly strong, as 
evidenced through histological observations in the pancreas of patients with chronic 
pancreatitis [38, 58]. Activation of fibroblasts leads to deposition of fibers during wound 
healing response; this is an evolutionarily conserved response to support the 
multicellular state of higher organisms [59]. Regulation of fibroblasts is coordinated 
largely through the transforming growth factor beta, TGFβ, signaling [59]. Other features 
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of wound healing processes include immune suppression, remodeling of the ECM, and 
increase of epithelial growth factors in order to recover cells lost through injury [60]. The 
role of increased stromal fibrosis in PDAC carcinogenesis is unchallenged as it 
enhances immune suppression, drug resistance, and promotes hypoxia—a feature 
associated with emergence of metastatic cells [61, 62]. Tumor cells activate quiescent 
pancreatic stellate cells (PSCs) through paracrine signaling from secretion of platelet 
derived growth factor (PDGF), TGFβ, and sonic hedgehog [61]. Upon activation, 
quiescent PSCs differentiate into alpha-smooth muscle actin myofibroblasts (αSMAs) 
allowing for further activation through autocrine signaling by PDGF, fibroblast growth 
factor (FGF), and TGFβ [61]. Unlike normal tissue where fibroblast activation is inhibited 
upon wound healing, in cancer PSCs are constitutively activated through cancer cells 
paracrine signaling. Thereby resulting in continuous deposition of fibers in the tumor 
stroma. 
Extensive evidence shows that PDAC cannot develop without activation of the 
desmoplastic stroma [61]. As evidenced by pharmacological inhibition of PSC activation 
in mice resulting in stromal collapse, development of smaller tumors, and overall more 
effective response to therapy [37]. Similar results were produced through inhibition of 
sonic hedgehog (SHH) signaling and upon depletion of enzymes responsible for 
hyaluronic acid (HA) deposition—a major component of PDAC tumor stroma [37, 61]. 
Contrastingly, it has also been demonstrated that depletion of carcinoma-associated 
fibroblasts and fibrosis through deletion of αSMA myofibroblasts themselves or SHH 
induces immunosuppression and accelerates PDAC progression and reduces survival 
[37]. These observations suggest that distinct components of the PSCs secretome have 
different properties in promoting or restraining tumor growth. The same logic can be 
applied for other tumor-stroma resident cells as well, such as macrophages whose 
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polarization as M1 leads to anti-tumorigenic response and M2 polarization leads to a 
pro-tumorigenic response [63]. Interestingly, these opposite properties may have a 
spatially and timely effects on selection of cancer cell populations, as this would lead to 
loss of a clonal population and replacement by a fitter clone. These waves of growth are 
likely to contribute to stochastic evolution of PDAC tumor.    
The PDAC stroma ECM is rich in HA, fibrillar collagens, and osteonectinn; 
collectively, these molecules make the dense stroma that functions as a physical barrier 
shielding the tumor [61]. Consequentially, increased fibrosis results in poor diffusion of 
oxygen to cancer cells resulting in wide spread hypoxia throughout the tumor [37]. 
Furthermore, HA is a negatively charged glycosaminoglycan that binds large amounts of 
water molecules leading to increased interstitial fluid pressure (IFP) [64]. Pathologic IFP 
occurs because of increased HA in stroma leading to swelling and collapse of the tissue 
vasculature thereby limiting oxygen diffusion [65]. It may seem detrimental but restriction 
of metabolic substrates oxygen and glucose would be a strong selection force for 
survival pathways such as autophagy, pinocytosis, endocytosis, as well as, metabolic 
reprogramming to compensate for glucose such as glutamine uptake [61, 62, 64-66]. 
Glucose diffuses radially 280µm away from blood vessels where as blood only diffuse 
200 µm; therefore, hypoxia posses a powerful selective force for survival in highly fibrotic 
tissue [10, 36]. Hypoxic TME is a classic feature of PDAC tumors, cells adapt to hypoxia 
through metabolic reprogramming to make better use of resources and continue 
proliferating [36]. The classical response to hypoxia is activation of hypoxia inducible 
factor HIF that functions as a master regulator of anaerobic metabolism and neo-
angiogenesis [62]. In addition to HIF response, oncogenic KRAS, other oncogenic 
mutations, as well as growth factors can also up-regulate glucose metabolism thereby 
promoting fitness in hypoxic microenvironment [39].  
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One of the hallmarks of cancer is the ability of cancer cells to kick start formation 
of new vasculature, neoangiogenesis [67]. Indeed, the cancer cells themselves can 
secrete angiogenic factors through inherent mechanisms or environmental mechanisms 
via HIF response [67]. Furthermore, factors secreted by PSCs such as osteonectin are 
known to induce neangiogenesis [68]. This means that the fibrotic stroma creates 
dynamic microvasculature leading to periodic cycles of moderate to deep hypoxia, which 
will favor selection of Warburg effect metabolism. Metabolic reprogramming is 
reminiscent of ecological studies that have shown success of invasive species through 
better utilization of limited resources to grow their population. A more elaborate depiction 
of metabolic reprograming and its role in cancer cell fitness will be provided in the 
upcoming sections. 
The Immune System in PDAC 
The immune system is one of the marvels of evolution that contributes to the 
overall homeostasis of multicellular organisms by eliminating foreign invaders through 
the combined action of specified cells, tissues, and organs. Thus, the immune system is 
critical in cancer prevention as it can recognize malignant cells as foreign entities and 
eliminate them. Evasion of immune response is critical for emergence of initial somatic 
mutations and metastasis, as cells need to avoid detection and continue their oncogenic 
processes [69]. Several lines of evidence suggest that the microenvironment of early 
pancreatic duct lesions is immunosuppressed [70]. Therefore, the immune system 
imparts selective pressure for mutant cells in early neoplastic lesions to develop 
mechanisms of immune evasion and produce a phenotype that can evade the immune 
response, as well as, other growth constraints. Where as in PDAC tumors, there is 
evidence the TME leads to T-cell suppression through accumulation of CD4 positive 
regulatory T-cells (Treg), M2 tumor-associated macrophages, and myeloid-derived 
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suppressor cells [70]. Accumulation of T-cells in the TME demonstrates that endogenous 
T-cells are functional, but upon arriving to the TME they become suppressed. 
Mechanisms of T-cell exhaustion include expression of inhibitory effectors (PD1, LAG3, 
TIM3), high-antigen tumor load, and immunosuppressive TME due to hypoxia or 
acidosis, as well as, limited nutrient access [71]. 
PDAC Metastasis 
Metastasis is managed clinically as late event in carcinogenesis, but from an 
evolutionary standpoint it is a reflection of clonal competition and fitness levels in the 
primary site. However, local tissue invasion itself is not a rate-limiting step in formation of 
metastases; this is because clonal expansion is a random process meaning that each 
replication cycle can yield metastatic cells, but PDAC progression seem to be a 
stochastic process and TME and cell population may drive metastatic selection of clones 
[72]. Furthermore, more than 99% of cells that enter the circulation do not survive in 
blood beyond 24 hours [52]. These observations suggest metastasis will be more likely 
with increasing tumor cell population growth; moreover, dissemination occurs from the 
earliest stages of pancreatic carcinogenesis meaning that PDAC tumors undergo rapid 
growth early in PDAC carcinogenesis. However, early carcinogenesis is an ambiguous 
term as PDAC goes undetected for years before diagnosis and thus its timely 
progression is not well described. Nevertheless, metastasis can occur on first replication 
cycle, but statistically it will be more favored upon establishment of primary tumor. 
Interestingly, no metastasis-specific genes have been found in pancreatic cancer; 
instead, a substantial proportion of metastatic efficiency is determined by the genetic 
alterations that arise during the clonal expansion phase (KRAS, CDKN2A, TP53 and 
SMAD4) [51, 52]. Thus, the genetic features of the parental clone play an instrumental 
role in determining the extent to which the clone will successfully adapt and survive in 
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foreign microenvironments. Evidence to support the notion that metastasis develops 
from evolution of cancer cells in the primary site comes from genomic studies of patients 
with metastatic lesions showing that the metastatic cell population arises from cells in 
the primary tumor site identified by their unique set of passenger mutations and 
structural rearrangements, which are genetic markers of the life history of that lineage 
[73]. Additionally, mathematical models factoring immune response, phenotypes, and 
stochastic evolution predict metastatic success least 5–10 years following development 
of the parental clone [51].  
These observations highlight the significance of timely adaptation of PDAC cells 
to the TME to achieve development of metastatic lesions. The complementary features 
for induction of metastasis of PDAC cells acquired in TME of the primary site that 
promote metastasis to the liver, lungs or peritoneum are still undiscovered. Evidence of 
selection for metastatic phenotype is shown in an interesting recent study of orthotopic 
PDAC mouse models where it was shown that organ-specific metastases are enhanced 
upon multi-clonal implantation [74]. Perhaps this is an artifact of competition and use of 
resources since PDAC cells lines have been shown to belong into three metabolic 
subtypes that are associated with glycolysis, lipogenesis, and redox pathways [75]. This 
implies that metabolism of PDAC cells plays a critical role in the phenotype of PDAC 
cells and whether they are primary site cells, metastatic, or therapy resistant. In the 
following sections the significance of metabolism in carcinogenesis with specific focus on 
PDAC. 
Cellular Metabolism 
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One of the hallmarks of cancer is up regulated metabolism this occurs because 
cancer cells are unresponsive to tissue-mediated growth inhibition, as well as, loss of 
intrinsic growth regulators (oncogenic mutations); thus cancer cells begin to proliferate 
uncontrollably. In the following section the role metabolism plays in cellular energetics 
and growth will be addressed. 
Metabolism refers to the biochemical processes within an organism through 
which energy and biomass are produced to sustain homeostasis and growth of an 
organism. Inside of a cell, nutrients are broken down and linked in a series of enzyme-
catalyzed chemical reactions also known as metabolic pathways. The reactants, 
products, and intermediates of these reactions are also referred to as metabolites. In a 
metabolic pathway the product of a reaction is the substrate for the next. Critical for 
metabolic enzyme-driven reactions are co-factors derived from vitamins or dietary 
minerals. There are two types of metabolic pathways: catabolic and anabolic. The 
function of the former is to break down metabolites, which release energy that is 
harnessed by the cell while the latter utilizes energy for biosynthesis of macromolecules. 
These two processes compliment each other because catabolism produces energy and 
anabolism consumes it during biosynthetic reactions. Figure 8, highlights catabolic-
anabolic relationship.   
Glycolysis, breakdown of glucose, is a ubiquitous metabolic pathway in all living 
cells. The glycolytic pathway takes place in the cytoplasm producing 2 pyruvate 
molecules and 4 adenosine triphosphate (ATP) molecules through substrate level 
phosphorylation of ADP (ADPàATP). ATP’s phosphate bonds hold potential energy, 
which generate free energy used by the cell when they are broken—hence ATP is the 
energy currency of the cell. However, 2 reactions in glycolysis require modification 
through phosphorylation, hexokinase [glucoseàglucose-6-phosphate] and 
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phosphofructokinase [fructose-6-phosphateàfructose-1,6-bisphosphate], because of 
this expenditure of energy glycolysis only produces a net of 2 ATP molecules for the cell.  
Approximately, 2.3 billion years ago the atmospheric levels of O2 increased to 
35%, today they are 21%, this caused a branching point in metabolism [76]. Glycolytic 
process uncoupled from oxygen became known as anaerobic metabolism or aerobic 
metabolism when coupled to oxygen. In anaerobic metabolism glucose-derived pyruvate 
is converted to lactic acid through a process called lactic acid fermentation. This process 
also reduces glycolysis co-factor nicotinamide adenine dinucleotide, NAD+ àNADH, 
which can then be recycled for sustained glycolysis. In aerobic glycolysis, glucose-
derived pyruvate is delivered to the mitochondrion—the cell’s ‘engine room,’ where it is 
converted into acetyl-coA via pyruvate dehydrogenase complex. Acetyl-coA is oxidized 
in a series of reactions collectively known as the tri-carboxylic acid (TCA) cycle using co-
factors nicotinamide adenine dinucleotide (NAD+) and flavin adenine dinucleotide 
(FAD+), which are reduced in the process—NADH, FADH2. Energy is generated through 
the electron transport chain (ETC), a system composed by a series of protein-complexes 
installed in the inner membrane of the mitochondria. The ETC conducts a series of 
reduction/oxidation reactions moving electrons from NADH and FADH2 to O2, which 
picks up protons and converts to water. Complex I,II, III and IV of ETC move protons 
produced through oxidation reactions in TCA cycle, into the inter-membrane of the 
mitochondria generating an electrochemical gradient. While, Complex V of the ETC re-
cycles protons back into the inner membrane of ETC using the potential energy 
movement of protons down their concentration gradient for ADPàATP phosphorylation. 
This whole process is possible because of oxygen is the final electron acceptor—hence 
the term oxidative phosphorylation. Reference [77].  
Metabolic Control 
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Aerobic metabolism generates more energy allowing approximately 1000 more 
reactions to take place compared to anaerobic metabolism, which led to generation of 
new metabolites enabling cellular biosynthetic potential [76]. For example, the oxidative 
decarboxylation of pyruvate to acetyl-CoA commits the carbon atoms of glucose to two 
principal fates: oxidation to CO2 by the citric acid cycle or incorporation into lipid via fatty 
acid synthesis. In eukaryotic cells the major metabolic control is through 
compartmentalization with glycolysis occurring in the cytosol and oxidative metabolism in 
the mitochondria. Enzymes are potential sites for regulation of metabolic pathways, 
more specifically enzymes catalyzing irreversible reactions. The significance of 
metabolic regulation is crucial for maintaining basal metabolic rates in normal cells. 
In glycolysis, the reactions catalyzed by hexokinase, phosphofructokinase, and 
pyruvate kinase are irreversible; thus, each of them serves as a control site with their 
respective function regulated by the reversible binding of allosteric effectors or by 
covalent modification. Allosteric regulation is mediated by a feedback loop of reaction 
and pathway products. In addition, the expression of these enzymes is tightly regulated 
by transcription factors in response to metabolic needs. The oxidative decarboxylation of 
pyruvate to acetyl-CoA is a critical branch point in metabolism. For this reason the 
activity of the pyruvate dehydrogenase complex is controlled by several means such as 
negative feedback of reaction products, as well as, covalent modification through 
Phosphorylation of the pyruvate dehydrogenase complex by pyruvate dehydrogenase 
kinase; while deactivation is reversed by pyruvate dehydrogenase phosphatase. 
Increasing the NADH/NAD+, acetyl CoA/CoA, or ATP/ADP ratio promotes 
phosphorylation and, hence, deactivation of the complex. For this reason the pyruvate 
dehydrogenase complex is switched off when the energy level is high and biosynthetic 
metabolites are abundant. The rate of the citric acid cycle is precisely adjusted to meet 
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an animal cell's needs for ATP. The primary control points are isocitrate dehydrogenase 
and α-ketoglutarate dehydrogenase enzymes through allosteric inhibition of pathway 
products. Thus, regulation of TCA cycle is primarily due to NADH/NAD+ or ATP/ADP 
ratio. Reference [77]. 
Metabolic regulation a balance for growth and survival 
Consider the fact that the biomass of microbes nearly doubles that of higher 
multicellular organisms. Needless to say, the number of microbial species far 
outnumbers that of multicellular organisms. This is because, microbes have been 
selected to grow as fast as possible when nutrients are available. Physiologically, this 
means that they need to re-wire their metabolic biochemistry from ‘survival mode’ to 
‘growth/replication mode’ in order to achieve this there must be a switch from basal 
metabolic rate to a metabolic rate competent to generate biomass required for 
exponential growth. Upon malignant transformation, cancer cells gain fitness and adopt 
a metabolic phenotype that is reminiscent of microbial exponential growth in order to 
produce an exact copy of itself. 
As previously described, normal cell function is maintained through the catabolic 
metabolism of glucose to generate free energy through oxidative phosphorylation. To 
sustain homeostasis and remain functional normal cells also need to undergo anabolic 
metabolic processes, which requires harnessing of biomass from nutrients to synthesize 
macromolecules as needed [56, 78]. ATP may be used for activation of some reactions, 
but anabolic processes need biomass and cofactors. Thus, it is illogical that all carbons 
would be maximized for energy production. For example, the synthesis of palmitate, the 
most common saturated fatty acid found in plasma membrane of animals, requires 7 
molecules of ATP, 8 molecules of acetyl-CoA, and 28 electrons from oxidized NADP+, 
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NADPHà NADP+. Similarly, the synthesis of amino acids and nucleotides requires more 
biomass and NADPH than ATP molecules. Oxidative metabolism of glucose yields a 
maximum of 36 ATP molecules and 2 NADPH molecules. NADPH will only be produced 
if glycolysis is branched into the oxidative arm of the pentose phosphate pathway (PPP). 
Thus, the amount of ATP produced through oxidative metabolism of glucose far exceeds 
its need. In the example of palmitate, a glucose molecule may provide 6 carbons while 
16 carbons are required for the fatty acyl chain. Similarly, a single glucose molecule can 
only reduce 2 NADP+ units; therefore, 7 glucose molecules are needed to make 
palmitate. These examples illustrate the fact that glucose cannot be committed to ATP 
synthesis entirely as it is counter productive for anabolic processes. Reference [56, 79] 
In addition to glucose, the amino acid glutamine is essential for bioenergetics, 
redox, and biosynthetic reactions. This is because glutamine is the most abundant 
amino acid in blood and muscle, for this reason, glutamine has become an essential 
metabolite for cell functions. For example, glutamine can be broken down through 
glutaminolysis to derive acetyl-CoA and generate energy via oxidative phosphorylation. 
Glutamine can also undergo anabolic pathways, annaplerosis, to synthesize 
macromolecule such as, non-essential amino acids (NEAAs), purines, pyrimidines, and 
fatty acids. Furthermore, glutamine is used to make antioxidant molecule glutathione. 
For this reason many cells shift their metabolism to be more dependent on glutamine for 
their survival, growth, and proliferation. Cells that become glutamine dependent show 
that up to 90% of their oxaloacetate is derived from glutamine. Glutaminolysis is a 
process exclusive to the mitochondria, it begins with uptake of glutamine and its 
conversion to glutamate by glutaminase enzymes (GLS1/GLS2), and glutamate is then 
converted into α-ketoglutarate via two diverging pathways. The canonical anaplerotic 
pathway occurs through action of glutamate dehydrogenase (GLUD). The second 
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pathway is via the non-canonical anaplerotic pathway is conducted by glutamate 
transaminase enzymes (GOT). Metabolic flux through the canonical pathway generates 
ammonia and NADH from decarboxylation of α-ketoglutarate in the TCA cycle. An 
interesting fact is that ammonia is an inducer of autophagy, a system through which 
glutamine is provided for metabolism. Contrastingly, the non-canonical pathway 
generates NEAAs instead of ammonia, including aspartate, alanine, and phosphoserine. 
Glutamine-derived OAA can condense with acetyl-CoA to make citrate, which is a 
substrate for ATP-citrate lyase (ACLY) for de novo lipogenesis via fatty-acid synthase 
(FASN). Glutamine-derived fatty acids can also be made through cytosolic isocitrate 
dehydrogenase (IDH1) in a caboxylation reaction. Similarly, glutamine-derived 
metabolites can be shuttled out of the mitochondria through shuttling mechanisms. For 
example, glutamine-derived aspartate can take part on the malate-aspartate shuttle and 
produce NADPH via malic enzyme 1 (ME1) or NADH through ME2 in the mitochondria 
compartment. Aspartate can also be converted to asparagine and participate in 
nucleotide synthesis pathways. Glutamine has been shown to play a critical role in cell 
metabolism and cells that rely solely on glutamine die upon depletion unless they 
undergo adaptation to glutamine depravation. Indeed, cells that are glutamine 
independent have increased expression of pyruvate carboxylase (PC), which converts 
pyruvate to OAA that is used to maintain TCA cycle if PDH is inhibited. Thus, when cells 
are stimulated to undergo growth the biosynthetic components: energy, biomass, and 
co-factors of reactions can be generated from glucose, amino acids (glutamine), and 
lipids (fatty acids). Reference [80]. Figure 9 highlights the canonical metabolic pathways. 
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Cancer Cell Metabolism 
A hallmark of cancer is the metabolic shift characterized by a marked increase in 
glucose uptake and subsequent lactic acid fermentation, compared to normal cells, in 
the presence of oxygen. German scientist Otto Warburg, hence the name Warburg 
effect discovered this phenomenon a century ago [81]. At the time, Warburg’s 
observation contradicted the Pasteur effect dogma, which described a metabolic shift 
between lactic acid fermentation and oxidative metabolism depending on oxygen 
availability. For nearly half a century, it was widely believed that cancer cells lacked 
functional mitochondria. However, the discovery of oncogenes and tumor suppressors, 
as well as, the improvement in genomic studies removed interest from cancer 
metabolism studies until the beginning of the 21st century. In the previous section, I have 
explained metabolic regulation and the theoretical role of anabolic metabolism upon 
growth stimulation. Cancer is characterized by uncontrolled cellular growth which, 
means that to produce viable cells during mitosis, a cancer cell must double its cellular 
content, which implies the synthesis of billions of nucleotides, lipids, and amino acids 
[56, 78]. Thus, cancer cells hijack cellular metabolism to maximize biosynthetic potential 
to produce macromolecules, energy, and maintain redox homeostasis. To achieve this 
functions and increase proliferation cancer cells exponentially increase glucose and 
glutamine uptake. Indeed, C13 glucose/glutamine uptake in glioblastoma shows that up 
to 90% of glucose and 60% of glutamine is committed to lactate synthesis [82]. The high 
rate of conversion of glucose and glutamine into lactate seen in cancer cells is mediated 
by lactate dehydrogenase A (LDHA). Inhibition of LDHA has shown to diminish growth of 
cancer cells possibly as it will limit secretion of excess carbon in a process recycles 
NADH, which is needed for continuous use glycolysis and TCA cycle metabolism [83]. 
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Similarly, increased glucose/glutamine uptake allows cells to generate NADPH 
necessary for anabolic pathways and redox homeostasis.  
Cells in a multicellular organism do not experience shortage or resources; thus, 
there is no selective pressure for optimizing metabolism for maximum ATP yield. 
However, selection for optimization of anabolic metabolic response does take place in 
effector cells of the immune system. This is because upon damaging injuries the body 
has to heal quickly in order to survive. Thus, it’s only logical that a fast responding 
immune system evolved. Cells capable of utilizing glucose and glutamine more 
effectively will proliferate faster. In the next section, I will elaborate on the development 
of PDAC metabolism. 
Hypoxia: Orchestrator of PDAC glycolytic metabolism 
Increased expression of key glycolysis enzymes in PDAC leads to a robust 
increase in metabolic activity and Warburg effect metabolic phenotype. These enzymes 
include, hexokinase 2 (HK2), phosphoglycerokinase 1 (PGK1), pyruvate dehydrogenase 
kinase isozyme 1 (PDK1), lactate dehydrogenase A (LDHA), enolase 2 (ENO2), and 
pyruvate kinase muscle 1 and 2 (PKM1,2), as well as, increase espression of membrane 
transporters such as glucose transporter 1 (GLUT1) and monocarboxylate transporters 1 
and 4 (MCT1,4) [66].  This metabolic shift is likely due in large part to stabilization of HIF 
complex because of hypoxia induced by strong desmoplastic reaction. HIF is regulated 
by oxygen perfusion therefore; when oxygen is depleted the HIF1α subunit of the 
complex is stabilized allowing for its interaction with HIF1β and subsequently recruitment 
to the nucleus as a complex to begin transcription of HIF response elements (HRE) [62, 
84]. The HIF response is a ubiquitous response for oxygen depletion and survival is 
promoted by increase in glycolysis and induction of neo angiogenesis [62, 84]. HIF1α 
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has an oxygen dependent degradation domain that is hydroxylated by propyl 
hydrolylases (PHDs). Hydroxylation of HIF1α allows for recognition by the von-Hippel 
Lindau binding protein, which is an E3 ubiquitin ligase that signals for HIF1α degradation 
[62, 84]. Because activation of HIF complex is a ubiquitous response mutations in the 
pathway are uncommon; however, the renal-cell carcinoma cell line RCC4 has shown 
mutations to VHL and as a result there is increased expression of HIF1α [85]. The role of 
HIF response in PDAC is undisputed and nearly 90% of tumors have increased 
expression of HIF1α. As a result PDAC cancers have increased glycolysis followed by 
high rate of lactate secretion. Figure 10 highlights HIF1α stability and HIF complex 
metabolic response.  
However, it is not conclusive to say that stabilization of HIF1α induced by the 
hypoxic TME is the cause of Warburg effect in PDAC. For example, hyperglycemia 
occurs as a result of diabetes type II, which predisposes for PDAC and it’s often a 
symptom of PDAC as well; replication of hyperglycemia conditions in vitro indicates an 
increase in HIF1α expression in normal oxygen conditions [86, 87]. Stabilization of 
HIF1α has also been demonstrated to occur upon growth factor signaling, PI3K, heat-
shock protein 90 (HSP90), and cyclooxygenase-2 activity (COX2) [88-91]. Other factors 
increasing HIF1α protein expression include ROS stress, nutrient depravation, growth 
factor signaling, metabolic disturbances such as increases succinate, as well as, protein-
protein interactions resulting in enhanced stability, acetylation, or phosphorylation [84, 
92].  For example, a study from our lab showed that the cytoplasmic terminal of MUC1 
associates with HIF1α promoting its stability and subsequent engagement in 
transcription of glycolytic genes [93, 94]. However, it is very likely that constitutive 
stimulation of HIF in PDAC is because of cyclic hypoxia throughout premalignant lesions 
and during establishment of primary tumor because of dynamic fibrotic stroma [95]. This 
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is consistent with the somatic evolution of PDAC to adopt Warburg effect metabolism 
independent of HIF, as it occurs in vitro. Thus, hypoxia response is critical because cells 
need to adopt this metabolic behavior to survive inconsistent oxygen perfusion due to 
growing stroma; where as normal ductal cells cannot survive prolonged absence of 
appropriate oxygen levels because hypoxic metabolic response will lead to tissue 
damage and turnover due to disruption of pH dynamics in exocrine pancreas [29]. 
Furthermore, PDAC cell lines with HIF1α depletion still exhibit increased glycolytic 
metabolism clearly indicating that the metabolic phenotype is maintained through 
oncogenic transformation, as it would promote fitness over normal cells [96].  
KRAS Orchestrator of PDAC glycolytic metabolism 
Oncogenic KRAS occurs almost ubiquitously in PDAC found in low-grade PanINs 
and with magnified expression in PDAC cells [38]. Its constitutive activity triggers several 
signal transduction cascades such as PI3K-AKT-mTOR, RAF-MEK1/2-ERK1/2 (MAPK), 
Ral-GEF, and Rho-Rac, which eventually relays signal to activate transcription 
mediators in the nucleus including c-MYC, NFκB, E2F, HIF1a, AP-1, and C-jun, 
Introduction Figure 4 [97, 98]. In this way, oncogenic KRAS effectively regulates a 
plethora of cellular activities such as cell growth, survival, migration, and metabolism. 
For these reasons oncogenic KRAS is essential for PDAC carcinogenesis. However, its 
expression alone is not sufficient to induce PDAC. As demonstrated in mouse models 
bearing only oncogenic KRAS that gives proliferation to cells in PanIN, but does not 
progress to PDAC likely due to tissue growth constraints [99]. Several lines of evidence 
suggest KRAS selects for Warburg effect phenotype. For example, transfection of 
oncogenic KRAS into human pancreatic ductal cells causes a moderate metabolic 
increase compared to PDAC cells; similarly, oncogenic KRAS (G12V) in embryonic 
kidney cells is known to induce up regulation of glycolysis at the cost of mitochondrial 
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dysfunction [100]. These examples also allude to the somatic evolution of PDAC to 
adopt Warburg effect metabolism. 
Oncogenic KRAS takes on metabolism through several effector pathways of 
which the most prominent are the PI3K-Akt and MAPK pathways [98, 101]. The PI3-Akt 
signaling pathway increases the transcription and translation of GLUT1, increase activity 
of phosphofructo kinase (PFK), localization of HK2 to the mitochondria thereby 
increasing rate of the reaction of glucoseàglucose-6-phosphate, and stabilization of 
HIF1α [102]. While the activation of MAPK pathway increases transcription rate of HIF1α 
[103]. Increased expression of HIF1α through RAS activity has been demonstrated in 
other RAS driven cancers through inhibition of PI3K and ERK [102-104]. Similarly, wild-
type RAS molecules overexpressed in in a variety of cancer types can be targeted by 
inhibition of farnesyl transferase, which anchors RAS molecules to the plasma 
membrane, resulting in metabolic stress due to reduced HIF1α expression [105-107]. 
1. KRAS driven glutamine addiction 
As previously stated, glutamine is the most abundant metabolite in blood and, 
along with glucose, it’s the major substrate for metabolic reactions in PDAC. Glutamine 
in PDAC is preferentially metabolized via the non-canonical anapleurotic pathway 
because of oncogenic KRAS expression. Indeed, a study by Son et al. found that KRAS 
plays a direct role in glutamine metabolism by increasing expression of GOT1 and 
reducing GLUD1 expression. In this way, oncogenic KRAS guides metabolic flux through 
the non-canonical pathway. These findings show that PDAC up regulates non-canonical 
glutamine metabolism in order to increase NADPH levels in order to maintain non-
cytotoxic ROS levels. Furthermore, this observation makes up for PDAC preference for 
non-oxidative PPP by providing the NADPH that otherwise would be generated through 
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oxidative PPP. Reference: [108]. Figure 11 highlights KRAS driven non-canonical 
anaplerotic glutamine metabolic pathway. 
2. KRAS re-directs glucose to PPP 
The Pentose phosphate pathway (PPP) is a biphasic, oxidative and non-
oxidative, cytosolic process that utilizes glucose, as the initial metabolite, and glycolytic 
enzymes to generate initial metabolic molecules. However, unlike glycolysis PPP is an 
anabolic process that produces 5 carbon sugars. The oxidative branch of PPP takes 
glcose-6-phosphate from hexokinase reaction as its initial metabolite, which is then 
converted to 6-phosphogluconolactone via glucose-6-phosphate dehydrogenase (G6PD) 
[glcose-6-phosphà6-phosphogluconolactone]. This irreversible reaction commits 
glucose to oxidative PPP and reduces 2 NADPà2 NADPH. Subsequently the reaction 
6-phosphogluconolactoneà6-phosphogluconate takes place via hydrolase 
gluconolactonase. The last step in oxidative PPP is the decarboxylation reaction of the 
6-carbon molecule via 6-phosphogluconate that reduces 2 NADPà2 NADPH [6-
phosphogluconateàRibulose-5-phosphate]. Production of NADPH through oxidative 
PPP is essential for suppression of oxidants using glutathione. This is because 
glutathione reductase (GR) oxidizes NDPH and reduces glutathione 
(GSSG+NADPHàGSH+NADP+), which is then oxidized by glutathione peroxidase 
(GPX) moving the electrons to hydrogen peroxide converting it to water [GSH + 
H2O2àGSSG + 2H2O]. This is noteworthy because GR is highly expressed in PDAC, as 
well as, high levels of NADPH indicating the significance of ROS homeostasis. 
Reference: [109, 110]. 
The non-oxidative PPP uses the 5-carbon sugar to generate intermediates for 
synthesis of nucleic acids and nucleotides. If there is a shift in metabolic demand for 
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ATP, pentose sugars from non-oxidative PPP can be recycled as intermediates of 
glycolysis, recycled as fructose-6-phosphate and glyceraldehyde-3-phosphate. Similarly, 
glycolysis intermediates can be used for nucleotide synthesis. This is the case of PDAC 
where oncogenic KRAS simulates glucose uptake and conveys glycolysis intermediates 
for biosynthesis of nucleotides and nucleic acids. The exact mechanism is not well 
understood; however, inhibition of MAPK and ablation of c-MYC results in decreased 
metabolic flux to non-oxidative PPP. Oncogenic KRAS makes up for loss of NADPH 
synthesis through oxidative PPP by induction of non-canonical glutamine metabolism, 
which increases NADPH needed for ROS homeostasis. Reference: [96, 109]. Figure 11 
highlights KRAS driven non-oxidative PPP pathway. 
3. Oncogenic KRAS Redirects Glucose to HBP 
The hexosamine biosynthetic pathway (HBP) links glucose metabolism and 
glutamine metabolism through Glucosamine-fructose-6-phosphate aminotransferase 
(GFPT) [fructose-6-phosphate+glutamineàglucosamine-6-phosphate]. This is the initial 
precursor in HBP for synthesis of UDP-GlcNAc (uridine diphosphate n-
acetylglucosamine), which is used by O-GlcNAc-transferase (OGT) for protein O-GlcNAc 
glycosylaton. Interestingly, PDAC have high levels of O-GlcNAc glycosylated proteins 
because of up regulation of HBP pathway enzymes and OGT, as well as, low levels of 
O-GlcNAcase (OGA), which catalyzes de-glycosylation. KRAS increases glucose and 
glutamine uptake, as well as, the expression of HBP rate limiting enzyme GFPT. 
Increased HBP activity has been linked with tumor invasion and metastasis. Reference: 
[96, 111] 
Post-translational modification of PFK1 via O-GlcNAc glycosylation has been 
shown to inhibit its activity thereby fluxing G6P to oxidative PPP or HBP [112]. 
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Furthermore, O-GlcNAc glycosylation stabilizes important transcription factors such as 
p53, c-MYC, and β-Catenin [113]. Increased metabolic flux through HBP promotes post-
translational and epigenetic alterations that promote carcinogenesis by increasing 
aneuploidy, as well as, secretion of insulin, TGFβ, and FGF [113, 114]. Thereby, 
promoting mutability and communication to other cancer cells and tumor stroma resident 
cells such as PSCs. Interestingly, HBP also modulates tyrosine kinase receptor signaling 
in PDAC shown by inhibition of OGT, which caused decrease in EGFR, ErbB2, ErbB3, 
and IGFR [113, 114]. Logically, glucose starvation reduces metabolic flux to HBP 
thereby decreasing protein glycosylation, but it must be highlighted that this leads to 
apoptosis by unfolded-protein-response [115]. Thus, protein glycosylation is critical for 
protein stability and function, which will be essential for PDAC cell proliferation. 
Furthermore, protein glycosylation is likely to mediate cellular differentiation by 
modulating cell-cell adhesion, responsiveness to GFs, immune system evasion, and 
signal transduction, through mechanisms not yet known. Thereby, HBP metabolic flux 
may play a critical role in neoplastic lesions. Figure 11 highlights KRAS driven HBP 
pathway.  
4. Role of KRAS in fatty acid metabolism 
In lung adenocarcinoma, it has been demonstrated a direct role of KRAS in fatty 
acid synthesis through activation of ERK2 pathway that increases FASN expression 
[116]. However, in PDAC the exact mechanisms of FA metabolism are not fully 
elucidated, but PDAC cell lines show increased expression of FAO and FASN. Studies 
comparing growth kinetics of normal ductal cells versus PDAC cells showed that a high 
lipid diet enhances PDAC cells more [117]. This indicates that PDAC cells can be 
stimulated to uptake lipids and used them for energy and biomass generation i.e. 
membrane backbone. These observations have been recapitulated using PDAC mouse 
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models fed a high fat diet versus low fat diet [118]. The high fat diet a marked increase in 
metabolic rate and energy production thanks to an increase in molecules that regulate 
uptake and oxidation of FAs. Indeed, high fat diets are known to be factors increasing 
risk of PDAC [119]. The role of FA and its regulating mechanisms in PDAC are not well 
known. Interestingly, it has been found that omega-3 FAs cause cancer cell death while 
omega-6 FAs correlate with incidence of cancer, including PDAC [119]. This may be 
because omega-6 FAs increase obesity, which incidentally increases cancer risk. 
Role of p53 in Metabolic Regulation 
Tumor suppressor p53 has long been shown to play key role in response to 
stress such as DNA damage, hypoxia, and oncogenic activation. Upon these events, 
p53 stalls growth (senescence) and induces apoptosis if damage is irreversible. To 
achieve these functions p53 must regulate the metabolic response to sustain cells viable 
upon stress. To intervene in metabolism, p53 interjects at many points in both glycolysis 
and oxidative phosphorylation and works to balance these metabolic pathways thereby 
inhibiting Warburg effect and growth associated with growth and carcinogenesis [120]. 
Therefore, loss of function of p53 will result not just in induction of mutations due to 
failing DNA damage response, but also loss of metabolic regulation furthering PDAC 
growth. 
p53 increases the expression of cytochrome C oxidase 2 (SCO2) a critical 
mediator of oxidative phosphorylation, as well as, GLS2 influencing canonical glutamine 
metabolism to sustain TCA cycle and oxidative metabolism [121, 122]. p53 modulates 
glycolysis as well by increasing expression of transporters GLUT1,4, and TIGAR (TP53-
induced glycolysis and apoptosis regulator) whose metabolic role is through inhibition of 
fructose-6-phosphate conversion to fructose-1,6-bisphosphate by increasing activity of 
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frucosebisphosphotase 2, which carries out the reverse reaction [120, 123]. In this way, 
p53 would redirect glycolysis intermediates to the oxidative PPP for production of 
NADPH and nucleotides. This function is critical for survival of cells upon replication and 
reactive oxygen (ROS) stress; p53 also reduces glycolysis by decreasing expression of 
phosphoglycerate mutase (PGM) [120]. In this light, it is easier to contextualize why 
deregulation of p53 is so critical for carcinogenesis. Furthermore, because of the 
contrasting role of p53 in inducing glycolysis for ROS or DNA damage response and 
induction of oxidative metabolism to suppress high glycolytic rate, the stability of p53 is 
critical to maintain basal metabolism and overall homeostasis. In PDAC the TP53 
mutation affects the p53 DNA binding domain thereby affecting transcription only the 
genes with a p53 response element; while other protein-protein interactions would 
remain thereby allowing formation transcription complexes where p53 is an activator of 
transcription [123]. For example, it has been observed that cells with p53 mutations to its 
DNA binding domain do not affect p53-related increased expression of glucose 
transporters [124]. Similarly, mutant p53 in liver tumors is implicated in high expression 
of HK2 thereby increasing the glycolytic rate of cancer cells [125]. Furthermore, the 
difference between basal levels of p53 versus increased levels of p53 during severe or 
sustained stress might allow for the transcription of different sets of genes and a different 
metabolic response. Thus, in PDAC p53 transcription may still occur as cellular stress 
will induce its expression. Figure 12 highlights p53 metabolic regulation. 
Increased expression of p53 has been demonstrated to increase intracellular 
ATP levels by up regulating oxidative phosphorylation as demonstrated in human colon 
cancer cell line HCT116 with high p53 versus HCT116 cells depleted of p53 [126]. This 
is achieved by increased expression of SCO2 a major component of the cytochrome c 
oxidase complex in the ETC, complex IV. p53 also induces the expression of GLS2 
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which converts glutamine to glutamate which can be used in the TCA cycle-ETC 
pathway when metabolized to α-ketoglutarate to generate energy or glutamate could be 
used in the synthesis of GSH to fight ROS stress [122]. Therefore, by increasing ATP 
yield p53 down regulates glycolysis through allosteric inhibition of its enzymes, 
previously reviewed. Wild-type p53 induces the transcription of p53-modulator-of-
apoptosis (PUMA) and BCL2-associated X protein (BAX) [127]. These proteins work 
together to create a pore in the outer membrane of the mitochondria and cause release 
cytochrome-c, which is used to activate caspase-mediated apoptosis. There is an 
interesting link between p53 and glycolysis, as it has been shown that increase glucose 
uptake suppresses PUMA expression [128]. Furthermore, pAKT causes inactivation of 
PUMA thereby enhancing glycolysis [129]. The role of p53 in regulation of cellular 
metabolism is highly complex because of the plethora of cell functions associated with it. 
PDAC p53 mutations targets its DNA binding ability while other protein-protein activity is 
not altered, which will have an effect in p53 functions such as metabolic regulation. 
Because of the prevalence of Warburg effect metabolism it is likely that mutant p53 
plays a role in maintaining glycolysis it as evidenced by increased PPP metabolic flux in 
PDAC or it may be that its metabolic regulating function is inhibited. 
1. p53 regulates FA metabolism 
FAs are important catabolic metabolic intermediates because they can undergo 
beta-oxidation to generate acetyl-CoA, which produces energy through TCA-ETC 
pathway [79]. Upon stress from DNA damage and glucose deprivation, p53 increases 
the expression of guanidinoacetate N-methyltransferase (GAMT), which mediates the 
conversion of glycine-derived guanidinoacetate to creatine for substrate level 
phosphorylation of ADP thereby increasing ATP/ADP ratio, as it occurs in glycolysis. 
Cancer cells can alter their metabolism by increasing de novo fatty acid (FA) synthesis 
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irrespectively of the levels of extracellular lipids [130]. Similarly, increased expression of 
FAO occurs in the livers of wild-type p53 mice, suggesting that p53 plays a role in 
energy maintenance through the FAO pathway [131] and FASN is a conserved p53 
target [132]. These observations suggest that wild-type p53 plays a role in linking FA 
metabolism to FA synthesis while mutant p53 leads FA metabolism to oxidative 
pathways. The role of mutant p53 in PDAC metabolic regulation has not been 
elucidated.  
Tumor Microenvironment Acidification 
Water is universal solvent of life, with a high tendency to undergo self-ionization 
[H20]ßà[OH-]+[H+]. However, free protons do not exist in solution so the equation is 
fixed to [H20] ßà [OH-] +[H3O+]. The rate at which water ionizes (Kw) is defined by the 
equation Kw=[OH-][H+]/[H20], which has been determined to be equal to 1.00 x 
1014 mol2 dm-6 at 25°C and 2.4 1014 mol2 dm-6 at 37°C. Therefore, the potential 
concentration of hydrogen ion [H+], pH, or hydroxide ion [OH-], pOH, at equilibrium is 
defined by [OH-]x107+[H+]x107=[H2O]10-14. The pH and pOH can then be calculated by 
taking the negative logarithm (-log) of the concentration (-log[H+] or -log[OH-] which means 
that at equilibrium 7+7=14 since pH+pOH=Kw. However, because the body has an 
internal temperature of 37°C and Kw=2.4 1014 mol2 dm-6, then the pH of water at body 
temperature is calculated to be 6.8. The pH scale defines the concentration of H+ in 
water solutions on a scale 1-14 with values <7 acidic and >7 basic. All biological 
solutions have a certain concentration of protons from the balance between protonation 
and deprotonation of water, weak acids, as well as, weak bases. For all living organisms 
pH regulation is critical as it regulates all biochemical functions. Changes in pH alter 3-
dimential protein structures altering their function and inducing denaturation. Therefore, 
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living organisms must maintain a narrow pH range through acid-base reactions, acids 
donate protons and bases donate hydroxide ions. Acid-base reactions exchange 
hydrogen ions with neutral molecules such as water (Arrhenius HA+H2Oßà A- + H30+) 
and to electrically charged ions such as ammonium, hydroxide, or carbonate (Bronsted 
Lowry HA + B ßà A- + HB).  
The equilibrium between protons and unpronotated molecules can be described 
by the acid dissociation equation, Ka, where Ka=[H+][A-]/HA]. Complex solutes such as 
biological molecules i.e. proteins are often given several Ka values because of their 
different proton binding sites. For this reason, the status of the protonatable site will vary 
with respect to pH. For example, at low pH due to high [H+] all protonatable sites will be 
filled, but with decreasing pH, low [H+], not all proton sites will be filled. Furthermore, 
because any given molecule has multiple Ka it can be titrated by adding base 
equivalents. Titration can be described by pH=pKa-log([HA]/[A-]) thus if the pKa is equal to 
the pH the concentration of base and acid are equal. Thus, a molecule with multiple 
protonatable sites also has multiple pKa values and isolectric points, pI= (pKa1-pKa2)/2, 
useful to indicate the pronation status of a molecule at a measured pH. Molecules with 
multiple protonatable sites are of major biological significance because they can function 
as buffers useful in preventing major pH changes that would alter cell function. Indeed, 
the sensitivity of proteins to pH changes is exceptional as it is a form of post-translational 
modification therefore ionization of a key amino acid will alter protein function. For this 
reasons, it is not surprising that only a narrow range of pH is permissible for livelihood of 
eukaryotic cells. Reference:[109, 133] 
Because of cellular metabolism, cells produce CO2 and lactic acids as a result of 
metabolic activity cells are net acid producers and the pHi has a tendency to fall. This is 
because lactic acid has a low pKa and deprotonates producing lactate- and H+ in 
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physiological pH, which is slightly basic ~pH 7.4. Meanwhile, accumulation of CO2 will 
promote its hydration to produce carbonic acid, which also has a low pKa relative to pHi 
and will deprotonate to produce bicarbonate and release of a proton. Therefore, when 
cells increased their metabolic rate they will face a dangerous challenge to maintain pHi 
because buffers can only reduces amplitude of pH changes but cannot remove excess 
protons. Thus, cells have to resolve to membrane transport. It is because the ability of 
biological membranes to selectively allow the passage of molecules that gives rise to 
difference between pHi and pHe, through selective transport of protons, as well as, 
molecules that release or take up protons such as CO2 thereby effectively maintaining 
pHi. The biological significance of protons highlights the essential function of regulating 
pH and to adapt to pH changes. In the following sections I will describe the role of 
metabolism and production of metabolic acids causing a decrease in pH of the TME. 
Reference: [109, 133, 134]. 
pH of Cancer Cells 
Physiological studies have established that oxygen and glucose diffusion in 
human tumors is approximately at a radius of 200 µm and 280 µm from blood vessels, 
respectively [135]. However, beyond the oxygen diffusion limit the tissue becomes 
necrotic. However, hypoxic areas where oxygen tension is 1% or less is associated with 
increase metastatic potential of cells and poor patient outcome. This is paradoxical in 
terms of fitness considering that nutrients will also be less and the fact that cancer cells 
proliferating cells require massive amounts of nutrients to generate biomass needed to 
generate a daughter cells, as previously described [56]. In addition to the challenge of 
oxygen and nutrient deprivation, cells in the PDAC TME must also endure the stress 
from excess metabolic acids produced by proliferating cells. Indeed, TME acidification is 
emerging as a hallmark of cancer [57]. Based on these observations it would be 
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predicted that the pHi of cancer cells is acidic, but it has been measured to be 
consistently above 7.1 so by this terms it is alkaline compared to pHe. This trans-
membrane distribution, pHi alkaline/ pHe acidic, of protons is not seen in normal tissues 
that have a balance of pHi 7.2/ pHe 7.4 [57]. These observations instigate two questions 
in cancer biology. First, how do cancer cells regulate tumor pH dynamics and, second, 
how those pH distribution contributes to carcinogenesis? 
The byproducts of metabolism in human cells are CO2 and lactic acid. If a cell 
has a high concentration of CO2 its hydration will take place generating carbonic acid 
whose pKa is 6.2 so it will deprotonate, CO2+H2OàH2CO3+H+. Similarly, lactic acid 
produced through fermentation has a low pKa of 3.2 and it will also dissociate, lactic 
acid+H2Oàlactate-+H3O+. Therefore, all cells are net acid producers; however, in living 
organisms CO2 is moved out of cells through passive transport because of its high 
lipid:water partition coefficient. Thus, CO2 modes into the capillaries where it is picked up 
by red blood cells and removed through respiration. While, protons are charged 
molecules and they cannot pass the lipid bilayer thanks to low lipid: water partition 
coefficient. Passive transport of H+ via monocarboxylate transporters (MCT1,4). The rate 
of CO2 and H+ venting depends on trans-membrane concentration gradients, which 
physiologically are maintained by coupling with capillary blood, which delivers oxygen 
and removes CO2. However, tumors are poorly perfused, especially PDAC tumors, 
which considerably alters venting of protons and CO2. Because of venting impediment 
the CO2 and H+ gradient will be high in the extracellular compartment thereby limiting 
their passive effusion. In addition to extracellular buffers (proteins), cells have developed 
adaptations to surpass the gradient rate-limiting step by cell surface expression of 
carbonic anhydrases that accelerate the otherwise slow hydration of carbon dioxide, 
CO2+H2OßàH2CO3ßàH+HCO3-, thereby facilitating CO2 and H+ venting, carbonic 
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anhydrase (CA) mediates the hydration/anhydration step. Thus, hydration of CO2 
requires mobilization of protons as well leading to increase in pHi and steady 
acidification of pHe. However, due to its stoichiometry coupling H+ with lactate-, requires 
an equal number of MCT proteins forcing cells to develop other means of transport 
across the membrane to maintain pHi. This is critical for cancer cells with high metabolic 
rate. Reference: [57, 133, 135, 136].  
In a given concentration where the Ka and buffer concentration are kept constant 
the only way of changing the pH is by adding base or acid equivalents, pKa=pH+pOH 
and 14=pH+pOH. Where as in living cells the solution is provided with protons as a 
result of metabolism. Thus H+/H+ equivalents only lowers the pH therefore cancer cells 
must actively transport protons out of the cell or import their chemical equivalents HCO3- 
or OH- to maintain pHi homeostasis. To balance pHi, membrane transporters must sense 
pHi changes and lead to a H+/H+ equivalent efflux so that the pH remains constant. To 
achieve this cells express membrane transporters to correct pHi disturbance such as: 
Na+/H+ (NHE), H+ ATPase, Na+/HCO3- (NCB) transporter, which work against Cl-/HCO3- 
exchanges (anion exchager, AE), and Cl-/OH- exchangers. Different types of transporters 
are reported in various combinations in normal cells, but bicarbonate transporter appear 
to be ubiquitous, were as, NHE appear to be cell type specific and dependent on 
conditions of environment. Most of these transporters depend on electrochemical 
potential of the molecules being transporter except for the H+ ATPase that hydrolyses 
ATP. By coupling the activity of pH regulation membrane transporters with signaling 
pathways cells can fine tune the metabolic response for steady state or 
growth/proliferation in accordance to intrinsic (normal or oncogenic) or extrinsic factors 
(growth factor, hormones, microenvironment). For example, NHE1 expression is 
enhanced upon acidosis of extracellular space during hypoxia or upon low HCO3- levels 
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in extracellular space. The signaling mechanisms inducing pHi control are still not 
understood completely.      
Active transport of proton equivalents is the way cancer cells prevent acidification 
of pHi, despite substantial acid load to the TME. However, this mechanism has two 
limitations being energy expenditure and pHe acidification. The energy commitment 
challenges cancer cells because they have high ATP demand for cell functions and are 
restricted to oxygen for oxidative metabolism. Therefore, pHi cannot operate at full 
capacity as demonstrated by decrease in NHE activity when ATP levels are low. 
Interestingly, the pH regulation system of removing proton equivalents does not 
eliminate protons with base equivalents therefore net pHe acidification occurs since 
tumor tissue is poorly vascularized, as in the case of PDAC. Even if it were possible to 
maximize metabolic capacity in combination with pHi control system will result in 
considerable acid load to TME, which will affect extracellular protein function as well as 
damaging the feedback for passive transport via MCT and CO2 effusion. Therefore, in a 
growing tumor pH dynamics are critical for survival of the cell as they are have to devote 
energy for pH homeostasis and growth. Reference: [57, 133, 135, 136]. Figure 13 
highlights the pHi regulators in cancer cells and a brief description is provided in table 2. 
Hypothesis 
Based on these observations, the evolutionary steps of carcinogenesis include 1) 
acquisition of oncogenic mutation and its fixation to the tumor landscape 2) clonal 
expansion of mutant cells 3) increase genomic instability leading to loss of tumor 
suppressors i.e. CDKN2A or TP53 4) Upon loss of check point cell cycle regulation 
stochastic growth of tumor cells may occur, but only cells that modulate the 
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microenvironment by generating desmoplasia will undergo further selection to further 
enhance fitness of cancer phenotype over immune cells and somatic cells; thereby 
promoting cancer metabolic phenotype and metastasis. 5) Because of hypoxia, high IFP, 
and oncogenic mutations cells are driven to adopt Warburg effect metabolism. 6) Cells in 
hypoxic regions of the tumor continue to be selected and become the most aggressive, 
but their survival is limited by regulation of pH dynamics, alkaline pHi and acidic pHe.  
In the last stage of this proposed model of the somatic evolution of PDAC, two 
factors fuel further growth and selection: metabolic phenotype and pH dynamics. PDAC 
cells are selected to grow uncontrollably, but the fibrotic TME prevents efficient 
ventilation of protons, which generates a challenge for regulation of pH dynamics. PDAC 
cells are studied in pH-buffered conditions and little information is known about the 
metabolic phenotype of cancer cells in low pH stress. Chapter 2 of this dissertation 
describes the study of PDAC cells in chronic low pH stress. For these studies, I 
hypothesized that in order to survive low pH stress the highly glycolytic PDAC cells must 
modulate their metabolism to reduce proton load into the extracellular space. I predicted 
a metabolic shift from Warburg effect metabolism and up-regulation of oxidative 
metabolism resulting in reduction of TME proton load by PDAC cells experiencing 
chronic low pH stress. These studies delve into the understudied low pH conditions of 
the PDAC TME and its effects in cellular homeostasis. These studies are highly 
significant to understand PDAC low pH stress response and identify therapeutic targets. 
Figure 14 shows a picture representation of this hypothesis.  
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Figure 1. Statistical data of PDAC diagnoses and survival rate. 1A) The ratio of 
diagnose/survival ratio of PDAC and how it has remained unchanged over the past two 
decades. 1B) The majority of PDAC cases are diagnosed as advanced disease, which is 
associated with increased mortality. Seer database: 
https://seer.cancer.gov/statfacts/html/pancreas.html [2]. 
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Figure 2. Changes of luminal pH in the exocrine pancreas during secretion. In 
physiological conditions acinar cells secrete digestive enzymes and protons, which 
acidify the acinar lumen. Ductal cells buffer the pH change by secreting bicarbonate. 
Adapted from Hegyi et al. [28] 
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Figure 3. Schematic representation of somatic evolution of cancer. Cells with mutations in 
PDAC have more fitness than wild-type cells. If these mutations are gained, the more fit mutant 
population will populate the tissue and may gain more mutations through injury or chronic 
inflammation. Malignant transformation is the result of cells budding off from the tissue basal 
membrane into the ductal lumen and modification of TME, which is the new selective force in 
carcinogenesis. The bordered text indicates the subsequent tumorigenic steps of PDAC cells.   
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Figure 4. Oncogenic KRAS and its downstream targets. Figure 4A. Wild-type KRAS 
is regulated by GEF and GAP, which regulate the KRAS GTP-bound form. Figure 4B. 
Oncogenic KRAS induces oncogenic signaling through ERK and AKT signaling 
cascades. Adapted from Vasan et al. [137] 
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Figure 5. Function of CDKN2A gene products in cell cycle regulation. p16INK4A 
functions in the RB tumor suppressor pathway through inhibition of CDK4/6 activity. 
p14ARF inhibits E3 ubiquitilin ligase MDM2 thereby preventing degradation of p53. The 
p53 pathway and RB pathway are integral in blocking inappropriate cellular proliferation. 
Figure adapted from LaPak & Burd [138] 
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Figure 6. p53 the guardian of the genome. The tumour suppressor p53 plays a 
critical role in maintaining genomic stability, apoptosis mechanisms, metabolism, and 
antioxidant defense. p53 is polyubiquitylated by the E3 ubiquitin ligase, MDM2, 
leading to its proteasomal degradation. However, in response to stimuli such as 
oxidative stress, hypoxia, oncogene activation and DNA damage, p53 becomes post-
translationally modified and stabilized to activate multiple pathways in response to 
cellular stress. Depending on the severity of DNA damage, p53 can induce cell cycle 
arrest, senescence, or apoptosis. p53 affects several metabolic pathways, including 
glycolysis, the pentose phosphate pathway and oxidative phosphorylation. 
Furthermore, p53 up-regulates antioxidant defense genes encoding reactive oxygen 
species (ROS)-removing enzymes that are important for cellular and genetic stability 
and thus contribute to the anti-tumour function of p53. Figure adapted from Siegl & 
Rudel [139]  
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Figure 7. PDAC progression. PDAC evolves from pre-malignant well-
characterized histologically evaluated pancreatic lesions, pancreatic intraepithelial 
neoplasms or PanINs. These pancreatic lesions are characterized by increased tissue 
disorganization and gaining of malignant mutations. The genetic signature of PDAC 
includes KRAS (PanIN-I) , INK4A (PanIN-II), TP53 (PanIN-III), and SMAD4 (PanIN-
III). Figure adapted from Iacobuzio-Donahue et al. [140]     
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Figure 8. Summary of mammalian cell metabolism. In catabolic metabolism 
nutrients are broken down to produce energy yielding metabolic by products. In 
anabolic reactions chemical energy generated through catabolism is used to generate 
building blocks of macromolecules through biosynthetic biochemical reactions.  
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Figure 9. Canonical catabolic pathways. Glucose, amino acids, and fatty acids are 
the main metabolic substrates for catabolic reactions. Amino acids can be 
metabolized into pyruvate and/or metabolic intermediates of the TCA cycle. Lipids can 
enter the TCA cycle through B-oxidation, a series of reactions where acetyl-coA is 
released from fatty acids. Similarly glycerol can be metabolized to enter to enter 
glycolysis metabolism as glyceraldehyde-3-phosphate. In this figure, the red circles 
indicate enzymes that are regulated; 4-sided square boxes indicate complexes that 
are regulated. In PDH complex the enzyme inhibiting is highlighted in red and the 
enzyme that promotes it is highlighted in green. Blue arrow represents the reaction in 
the opposite direction. Green boxes and green arrows represent the chemical energy 
generated at the end of each pathway.  
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Figure 10. Hypoxia inducible response leads to metabolic reprogramming. 
Figure 10A. Stress factors regulate HIF1α stability through posttranslational 
modification enabling stability of HIF1α allowing formation of the HIF complex through 
interaction of HIF1α and HIF1β. The canonical mechanism of HIF1α stability is 
hypoxia (in bold font). Decreased oxygen levels inhibit hydroxylation of HIF1α by 
propyl hyrdoxylases (PHDs), which prevents its recognition by E3 ligase von Hippel-
Lindau (VHL), and subsequent proteasome degradation. When stable, HIF complex 
binds HRE sequences to induced expression of target genes. Figure 10B. HIF target 
genes include glycolysis rate limiting enzymes, glucose transporters, as well as, lactic 
acid fermentation enzyme LDHA and MCT4 for rerelease of excess lactate. HIF also 
increases expression of PDK which henbits PDH complex though phosphorylation 
thereby uncoupling glycolysis from oxidative metabolism.   
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Figure 11. Oncogenic is a master regulator of PDAC metabolism. KRAS diverts 
glycolysis intermediates of metabolism into the HBP by inducing overexpression of 
GFPT1. Similarly, KRAS induced expression of RPIA and RPE to divert glycolysis 
intermediates to the non-oxidative PPP. KRAS also inhibits GLUD1 and 
overexpresses GOT1 allowing glutamine to be metabolized through the non-canonical 
pathway. Figure adapted from Perera & Bardeesy [141] 
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Figure 12. p53 mediated metabolic regulation. p53 regulates glucose catabolism in 
cancer cells through effectors such as TIGAR, PGM, GLUT1/4, IKK, HKII, SCO2, 
GLS2, and G6PD. These proteins work together to enhance oxidative metabolism and 
reduce glycolysis and PPP. Figure adapted from Shen et al. [142]  
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Figure 13. Major pH regulators in a cancer cell. Hypoxia and oncogenic driven 
Warburg effect metabolic shift to increase lactate production from glycolysis or 
glutamine. Similarly, reductive decarboxylation produces protons from excess CO2 
(CO2+H2OàH2CO3àH++ HCO3-). CO2 moves passively across the plasma membrane 
and is converted to carbonate by carbonic anhydrases. Protons are pumped out by 
MCTs, NHE, and V-ATPase; while buffer (HCO3-) is imported by NBCs and AEs (BT). 
Figure adapted from Damaghi et al. [143] 
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Figure 14. Hypothesis. In normal (physiological pH), PDAC cells are able to conduct 
Warburg effect metabolism because cellular proton load into the TME is buffered. 
Reduced buffering of pHe creates a significant difference between cytosolic-extracellular 
[H+] gradient. In this conditions release of protons from metabolic reactions of glycolysis 
will not be favored, as the electrochemical gradient will rather favor the inward flux of 
protons. Cancer cell growth is stalled at pHi value bellow 7.2 further decrease in pH will 
induce apoptosis. Thus, the cells must reprogram their metabolism to diminish production 
of metabolic acids—lactic acid. Thus, they must switch to depend on oxidative 
phosphorylation to make energy for cellular homeostasis in stress conditions. 
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Table 1 A 
Disease		
Factor	
Mutated		
Genes	 PDAC	Increased	Risk	
Hereditary breast and 
ovarian cancer syndrome BRCA1, BRCA2, PALB2 2-3.5 
Lynch syndrome (hereditary 
non-polyposis colorectal 
cancer) 
MLH1, MSH2, MSH6, 
PMS2, EPCAM 8.6 
Familial adenomatous 
polyposis APC 4.5-6 
Peutz-Jeghers syndrome STK11/LKB1 132 
Familial atypical multiple 
mole melanoma pancreatic 
carcinoma syndrome 
P16INK4A/CDKN2A 47 
Hereditary pancreatitis PRSS1, SPINK1 69 
Cystic fibrosis CFTR 3.5 
Ataxia-telangiectasia ATM Increased 
 
 
Table 1B 
 
 
 
 
 
 
Risk factor Increased PDAC risk 
Current cigarette use 1.7-2.2 
Current pipe or cigar use 1.5 
> 3 alcoholic drinks per day 1.2-1.4 
Chronic pancreatitis 13.3 
BMI > 40 kg/m2, male 1.5 
BMI > 40 kg/m2, female 2.8 
Diabetes mellitus, type 1 2 
Diabetes mellitus, type 2 1.8 
Cholecystectomy 1.2 
Gastrectomy 1.5 
Helicobacter pylori infection 1.4 
Table 1. The risk of PDAC is elevated by intrinsic factors such as familial diseases 
associated with loss of tumor suppressor genes and the risk of PDAC is also 
elevated by extrinsic factors such as alcoholism and obesity. Table 1A. Intrinsic 
factors associated with PDAC. Table 1B. Extrinsic factors associated with PDAC risk.  
[144] 
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Table 2 
Name  Abbreviation  Description 
Carbonic 
Anhydrase II CAII 
Carbonic anhydrases catalyze the conversion of 
carbon dioxide, the final product of oxidative 
phosphorylation, and water to produce carbonic acid 
which deprotonates in pHi to generate bicarbonate 
and protons. CAIX and CAXII are transmembrane 
CAs that has been identified to play roles in tumor 
progression and metastasis. CAIX is a target of 
HIF1α its expression is up regulated in hypoxic 
regions of tumors. Intracellular CAs such as CAII will 
dehydrate metabolically produced bicarbonate into 
aqueous CO2 in a reaction consuming a proton 
thereby promoting passive transport of CO2 [143, 
145]. 
Carbonic 
Anhydrase IX CAIX 
Carbonic 
Anhydrase XII CAXII 
Anion exchanger 
Cl-/HCO3- 
AE, SLC4 
family 
These transporters facilitate the movement of 
HCO−3 ions across plasma membranes to either 
acidify or alkalinize the pHi [143, 146]. Sodium 
bicarbonate 
exchanger 
Na+/HCO3- NBC family 
Anion transporters SLC26 family 
Aquaporins AQP 
Sodium hydrogen 
exchanger Na+/H+ NHE1 
NHE1 is the most common isoform of the 
Na+/H+ exchanger. NHE1 is the most active 
transporter in pHi homeostasis. It uses the sodium 
electrochemical gradient to extrude H+ when the 
cytosolic pH becomes too acidic. NHE1 functions as 
a pHi sensor during intense metabolic activity. NHE1 
is known to be activated by EGF signaling as well 
[143, 147]. 
Vacuolar ATPase  V-ATPase 
V-ATPases pump protons out of the cytoplasm and 
into intracellular vesicles such as lysosomes using 
free energy from ATP hydrolysis [148]. 
Monocarboxylate 
Transporter 1 MCT1 
MCTs transport mono-carboxylic acids such as 
lactate, pyruvate, and ketone bodies into and out of 
cells across plasma and mitochondrial membranes. 
Only 4 isoforms, MCT1–MCT4, have been 
functionally characterized as proton-linked 
monocarboxylate transporters. MCT1 and MCT4 are 
commonly overexpressed in tumors as they are 
essential in regulating the cytosolic efflux of lactate 
and protons produced through HIF or Warburg effect 
up-regulated glycolysis. Therefore, their expression 
is critical to maintain pHi homeostasis at the expense 
of contributing to extracellular acidosis [145, 149].  
Monocarboxylate 
Transporter 4 MCT4  
 
Table 2. Membrane transporters regulating pHi. 
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Chapter 2 
Results: 
GOT1-Mediated Anaplerotic Glutamine 
Metabolism Regulates Chronic Low pH 
Stress in PDAC Cells  
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Introduction 
Metabolic alterations represent an important hallmark of cancer cells [150]. 
Metabolic reprogramming allows cancer cells to sustain uncontrolled proliferation by 
rapid generation of ATP, biosynthesis of macromolecules, and maintenance of redox 
status [151]. Cancer cells can also reprogram the major metabolic pathways 
(carbohydrates, proteins, lipids, and nucleic acids) in order to meet these basic demands 
for uncontrolled proliferation [56, 152]. The characteristic metabolic phenotype seen in 
cancer cells is the Warburg effect, which operates by enhancing glucose uptake and flux 
into glycolysis, while simultaneously diminishing the glucose carbon flux that enters the 
TCA cycle in the mitochondria, even in the presence of oxygen [36, 153]. Although ATP 
generation through substrate level phosphorylation is very rapid, this mechanism is far 
less efficient than oxidative phosphorylation in generating energy from glucose. Thus, 
the metabolic phenotype observed in the Warburg effect demands very high glucose 
uptake to meet the energetic, biosynthetic, and redox needs of cancer cells. For this 
reasons the increased glucose uptake of cancer cells is useful for diagnosing cancer 
using radiolabeled glucose analog 18F-fluorodeoxyglucose and positron emission 
tomography (FDG-PET) to image and evaluate tumor progression without the need of a 
biopsy [154, 155].  
Because of the enhanced metabolic rate of rapidly proliferating tumor cells, the 
glucose that is metabolized through substrate level phosphorylation produces lactic acid 
as the end product. Lactic acid is a weak acid with pKa with approximately ~pH 4, and 
thus, it quickly dissociates loses a hydrogen ion [156]. Lactate is transported outside of 
the cell by monocarboxylate symporters along with protons resulting in decreased pH in 
the extracellular milieu [157, 158]. Intracellular hydrogen ions can also be removed by 
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sodium hydrogen exchangers that import sodium ions and extrude hydrogen ions, 
thereby acidifying the extracellular environment [159, 160]. Similarly, vacuolar ATPases 
extrude hydrogen ions against their concentration gradient to the extracellular space, 
and hence, lower the extracellular pH [161]. In vitro studies have shown that rapidly 
growing cells, which exhibit the Warburg effect, increase the expression of these cell 
surface proteins to maintain an alkaline intracellular pH environment [57, 162]. Indeed, 
increased intracellular pH is an established permissive signal for cellular proliferation 
promoting survival by limiting apoptosis, a process that is associated with intracellular 
acidification [163, 164]. The role of low extracellular pH in carcinogenesis is thus 
paradoxical: on one hand alkaline intracellular pH promotes proliferation and survival, 
while at the same time, extracellular pH promotes invasion and metastasis at the cost of 
inducing stress, senescence, and apoptosis [159, 165, 166].  
In addition to glucose, glutamine metabolism is also essential for the proliferation 
of cancer cells. Recent studies have demonstrated that glutamate derived from 
glutamine is utilized by highly proliferative cells to generate non-essential amino acids 
(NEAAs) through the glutamic-oxaloacetic transaminase enzymes (GOT1 and GOT2), 
while quiescent cells metabolize glutamate through GLUD1 (glutamate dehydrogenase 
1) and subsequent decarboxylation reactions in the TCA cycle [167, 168]. Thus, 
glutamine can be metabolized through both anabolic (anaplerotic) and catabolic 
pathways.  
Several oncogenes are implicated in reprogramming tumor cell metabolism. One 
such gene is KRAS, which upon accumulating activating mutations serves as a key 
signature oncogene that serves a prominent role in malignant transformation and tumor 
progression in PDAC [5, 169]. PDAC cells with oncogenic KRAS have reprogrammed 
glucose and glutamine metabolism to serve anabolic processes [96, 108]. Canonical 
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glutamine metabolism occurs through glutamate synthase (GLS)-mediated conversion of 
cytoplasmic glutamine into glutamate. Glutamate is then metabolized in the mitochondria 
through GLUD1 into alpha-ketoglutarate that enters the TCA cycle [170]. The non-
canonical pathway metabolizes glutamate to aspartate and alpha-ketoglutarate through 
GOT2; aspartate is subsequently metabolized to oxaloacetate by GOT1 in the cytosolic 
compartment. Aspartate is metabolized by malate dehydrogenase  (MDH) to malate, 
which is then metabolized by malic enzyme (ME) to produce pyruvate. These anaplerotic 
reactions increase the NADPH/NADP ratio thereby maintaining ROS balance. PDAC 
cells are dependent on these reactions for maintenance of intracellular ROS levels as it 
is evidenced by the decrease in cell survival upon knockdown of enzymes in the 
pathway. 
Due to metabolic reprogramming by oncogenic KRAS present in 90% of PDAC 
cases, extracellular acidification is highly abundant. While the regulation of pH in cancer 
cells has been studied thoroughly, the metabolic adaptations to chronic low ph induced 
stress are not well defined. Therefore, in the current study, we investigated the metabolic 
basis of adaptation to chronic low pH stress in PDAC cells, which exhibit high glycolytic 
capacity, by subjecting them to chronic low ph. We utilized PDAC cells with oncogenic 
KRAS to identify the metabolomic alterations in PDAC cells under chronic low ph and 
identify vulnerabilities for therapy. Here, we report a pronounced increase in non-
canonical anaplerotic glutamine metabolism, which serves the bioenergetic needs and 
maintains ROS balance in cells undergoing acidosis stress.  
Materials & Methods 
Cell lines: 
	 68	
Cell culture of PDAC cell lines S2-013 and Capan-1 have been described 
previously [93, 171]. The S2-013 and capan-1 cell lines were obtained from a liver 
metastases of PDAC patients. In immunodeficient nude mice orthotopic implantation, 
Capan-1 and S2-013 forms a tumor that produces mucin and is morphologically and 
biochemically similar to the PDAC tumor of origin. Capan-1 and S2-013 cell lines both 
bear activating KRAS mutation, mutant TP53 affecting p53 DNA binding, and 
homozygous deletion of CDKN2A/p16. While, SMAD4 has no alterations and Capan-1 
have shallow deletions, cosmic database. Cells were validated by STR profiling.      
Control pH culture: 
Cell lines were cultured in high glucose high glutamine Dulbecco’s Modified 
Eagle Medium (DMEM) (Hyclone) containing 4.5g/L glucose (Sigma-Aldrich) and 
0.584g/L glutamine (Sigma-Aldrich). Additionally, 1mM sodium pyruvate and 5% FBS 
were supplemented to complete the media. To set control pH 3.7g/L NaHCO3 were 
used, this concentration sets pH of media approximately to ~7.4 at 37 degrees Celsius, 
and phenol red in DMEM indicates pH changes. The media was replaced every 24hrs to 
maintain pH from metabolic acids produced by cell growth.  
Low pH cell culture: 
Cell lines were cultured in high glucose high glutamine Dulbecco’s Modified 
Eagle Medium (DMEM) (Hyclone) containing 4.5g/L glucose (Sigma-Aldrich) and 
0.584g/L glutamine (Sigma-Aldrich). Additionally, 1mM sodium pyruvate and 5% FBS 
were supplemented to complete the media. To set low pH conditions 1g/L NaHCO3 were 
used, this concentration sets pH of media approximately to ~6.9-7 at 37 degrees 
Celsius, and phenol red in DMEM indicates pH changes. Low pH media with values 6.7 
and 6.4 was prepared using 0.5 and 0.1 g/L NaHCO3 respectively. The media was 
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replaced every 24hrs to maintain pH from metabolic acids produced by cell growth. 
Lactic acid was used to decrease the pH of media, but the pH was very inconsistent 
being very acidic without sodium bicarbonate and titration with bicarbonate or hydroxide 
equivalents. The organic zwitterionic organic chemical buffer HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) was used as well, but it required addition 
of HCl equivalents to lower the pH to 7.0 and it was not maintained in the incubator. To 
establish chronic low pH exposure, cells were cultured in pH 6.9~7.0 continuously for 14 
days using bicarbonate as the buffer of choice. The media was changed every 24 hours 
during this period. 
pH maintenance during in vitro incubation: 
The pH value of the media is critical for growth of cells in culture and should be 
buffered to pH 7.4 in order to replicate physiological conditions. Thus the conditions in 
the incubator are 20% oxygen, same as atmosphere, and 5% for CO2 to replicate blood 
levels, 40mmHg. Oxygen is not a polar molecule therefore it will not dissolve in water, 
but CO2 will dissolve in water forming carbonic acid. However, because the pH of 1L 
DMEM is 6.6 without NaHCO3, carbonic acid will quickly dissociate because of its acid 
dissociation constant (Ka) being lower than that of the pH of the media producing 
bicarbonate and protons. Furthermore, Henry’s law of gas solubility states that at a 
constant temperature of 37°C the amount of CO2(g) that dissolves in the media is 
directly proportional the partial pressure of CO2(g) in equilibrium with the media. 
Therefore, conversion of gas to aqueous CO2 is described in the following equation, CO2 
(aq)ßàCO2(g)+H2O(l), at constant equilibrium (Keq) conversion is defined by 
Keq=[CO2(g)[H2O(l)]/[CO2(aq)] and assuming that water concentration is constant we can 
define the equation as a dissolving constant of gas pressure, KH, which also defines the 
partial pressure of the gas that is dissolved thus KH=Keq/[H2O]=pCO2/[CO2(aq)]. In this 
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way the equilibrium constant can be calculated for 1M of CO2 which is KH=29.41 and 
applying this to the 5% CO2 in the incubator which equates to 38mmHG or 0.5 ATM the 
amount of dissolved CO2 gas in the incubator is 1.7x10-3M, KH=pCO2/[CO2(aq)] then 
[CO2(aq)]=pCO2/KH. Therefore, CO2 (g) gas that dissolves in the incubator will exist as 
bicarbonate HCO3- , CO2(g)+H2OàH2CO3à HCO3-+ H3O+. For this reason, to replicate 
physiological pH of 7.4 the pH must be adjusted using buffers systems such as natural-
buffer system by adding bicarbonate and/or chemical buffering using zwitterions. For this 
study I opted to buffer pH using the natural-buffer system (bicarbonate). The human 
body has a reserve of NaHCO3, from kidney, and plenty of HCO3- circulating in the 
blood, which is very useful to maintain blood pH at 7.4 by removing protons using the 
vascular system. Protons generated from metabolic acids combine with HCO3- to form 
H2CO3, because of the increased concentration of bicarbonate the reverse reaction 
occurs and carbonic acid is converted to CO2 and water. Excess CO2 in blood is picked 
up by red blood cells (RBC) and undergoes the following reaction 
CO2+H2OàH2CO3àHCO3-+H+ with the first reaction catalyzed by carbonic anhydrase 
(CA). This mechanism is essential for delivery of oxygen to tissues because increased 
protons in RBCs reduces hemoglobin binding affinity to O2 causing its release into 
tissues. At the same time cells exchange HCO3- for Cl-, through anion exchanger (AE), 
thereby increasing plasma CO2 and maintain a high pCO2 for O2 delivery. In the lung, 
pO2 increases and forces protons of Hb allowing O2 to bind Hb. The accumulation of 
protons leads to a shift in AE and bicarbonate is imported and combines with protons to 
form carbonic acid that is converted to water and CO2 by CA, H++HCO3-
àH2CO3àCO2+H2O. The human body is an open system and CO2 is removed as gas 
from lung alveoli. However, cells in an incubator are not an open system and media 
must be changed to maintain constant pH since buffers can only contain excess 
accumulation of protons not remove them. The pH of control media was set to ~7.4 
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using 3.7g/L of NaHCO3, which dissolves in the media to form sodium ions and 
bicarbonate (NaHCO3àNa+ + HCO3-). The pKa of carbonic acid is 6.4 and carbonate is 
10.2 indicating that the isoelectric point is 8.3, pI=1/2(pKa1+pKa2). Therefore, at pH 7.4 
the solution contains a higher amount of bicarbonate than at pH 7.0, therefore the higher 
concentration of NaHCO3 has more base equivalents to counter metabolic acids for a 
longer time. Reference: [172]. 
GOT1 Knockdown: 
Cell transfections for producing replication-incompetent lentivirus were performed 
by utilizing Turbofect followed the manufacturer’s protocol [93, 173]. Stable short hairpin 
RNA (shRNA) constructs were obtained from Sigma-Aldrich: shGOT1 (34784; 
CCGGGCGTTGGTACAATGGAACAAACTCGAGTTTGTTCCATTGTACCAACGCTTTTT
G) and shGOT1 (34785; CCGGGCTAATGACAATAGCCTAAATCTCGAGATTTAGGC 
TATTGTCATTAGCTTTTTG). Cells were transfected in control pH culture conditions and 
after puromycin selection and knockdown validation clones were plated in low pH for 14 
days to establish chronic low pH expossure. Cells were validated by STR profiling.  
Metabolomics: 
Polar metabolite isolation was performed as described previously [174]. In short, 
0.75×107 cells were cultured for 24h in normal DMEM. Cells were then washed with PBS 
and culture medium was exchanged with fresh medium 2 hours before metabolite 
extraction, the pH of the media was maintained. Cells were frozen in dry ice and polar 
metabolites were then extracted with 80% methanol by plate scraping. Metabolite 
extracts were subjected to LC-MS/MS analysis using multiple reaction monitoring 
methods described previously [175]. Data acquisition was carried out utilizing 
AnalystTM1.6 software (AB SCIEX) and peaks were integrated with MultiquantTM (AB 
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SCIEX). Peak areas were normalized to the respective protein concentrations in both 
culture conditions. Extraction and analysis of polar metabolites was performed three 
times after cells had been grown in low pH for 14-days.   
Reactive oxygen species assay: 
Reactive oxygen species levels were determined by using oxidation-sensitive 
fluorescent dye 2’,7’–dichlorofluorescin diacetate (DCFDA). Control and low pH cells 
were seeded at 3.0×104 cells per well in a clear bottom black 96-well plate. After the cells 
adhered, the media was replaced with fresh DMEM containing 10 µM DCFDA, with or 
without respective treatments. H2O2 was used as a positive control and N-acetyl cysteine 
(NAC) was used as a negative control. Control and treated cells were incubated at 37°C 
for 30 mins. The cells were washed with PBS and 100µL of PBS was added to the wells 
for measuring the emission of DCFDA using Biotek Cytation3 plate reader. DCFDA was 
measured using an excitation of 495nm and an emission of 529nm. These experiments 
were repeated two times with similar results. The same experiment was repated using 
ROS-insensitive dye 5(6)-Carboxy-2’,7’-dichlorofluorescin diacetate (CDCFDA) as a 
negative control and H2O2 as a positive control. 
Growth Kinetics: 
To determine growth kinetics, 2.5×105 cells were seeded in 12-well tissue culture 
plates in control and low pH media. These cells were trypsinzied at 24, 48, 72, and 96 
hours after cells were attached to the plate. If cells received treatment, this was re-
applied every 24 hours. Once collected, cells were stained with trypan blue (Gibco) and 
counted using BioRad TC20 automated cell counter.  
Colony formation assay: 
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Cells were seeded in 6-well tissue culture plates at 200 cells per well or in 12-
well plates at 50 or 100 cells per plate. Cells were allowed to attach to the plate for 48 
hours and then media replaced with fresh media every 72 hours. Colonies were allowed 
to form for 14 days. Colonies formed at the end of experiments were washed, fixed in 
methanol, and stained with 0.4% crystal violet in 25% methanol. Colonies containing >50 
cells for each well were counted. This experiment was repeated with 100 and 200 cell 
numbers showing similar results.  
Cell cycle analysis: 
Cell were seeded at 20% confluence in 60mm tissue culture plates and allowed 
to adhere to the plate overnight. Cell growth was synchronized using the double 
thymidine block previously described [176]. After synchronization, cells were cultured in 
fresh media for approximately 20 hours before collection for cell cycle analysis. Cells 
were fixed with cold ethanol and stained with Telford reagent (16.81mg EDTA, 13.4 mg 
of RNAse A, 25mg of propidium iodide, and 500µL of Triton X-100, dissolved in 500mL 
of milli-q water). These samples were submitted for analysis to the University of 
Nebraska Medical Center flow cytometry research facility. This experiment was repeated 
twice yielding similar observations.   
Glucose/Glutamine Uptake: 
Cells were seeded at a density of 5×104 cells per well in 24-well plates and 
allowed to adhere overnight before conducting the experiment. Cells were cultured in 
glucose and glutamine, and pyruvate containing DMEM and 5% fetal bovine serum. 
Cells were seeded in eight replicates 3 for background, 1 for counting (normalizing), and 
4 for radiolabeled metabolite uptake. For the glucose uptake assay the cells were 
starved for 2 hours in DMEM without glucose, glutamine, pyruvate, and fetal bovine 
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serum. After 2 hours the background wells were supplemented with 50x the normal 
concentration of glucose for 20 minutes. Control and low pH cells were then incubated 
with tritiated [3H]2-Deoxy glucose, washed with PBS, and lysed with 1% SDS. The 
lysates were counted for [3H] by a scintillation counter. For glutamine uptake assay, cells 
were incubated with [3H] glutamine, but background cells were not.  Cells were 
subsequently washed with PBS, lysed with 1% SDS and lysates were counted for [3H] by 
a scintillation counter. These experiments were repeated three times with similar results.     
Lactate Release: 
Control and low pH cells were seeded in 24-well plates at 5×104 cells. After 12h, 
the culture medium was replaced with fresh phenol red free DMEM set to pH 7.4 and pH 
7.0. Cells were cultured for 24h and the culture supernatants were then used to 
determine lactate release by lactate assay kit (Eton Bioscience Inc., San Diego, CA, 
USA), per manufacturer protocol. This experiment was repeated twice yielding similar 
observations.   
ATP assay: 
Cells were seeded at 5×105 cells per well in a 12-well tissue culture plate. The 
cells were maintained in control and low pH DMEM. After 24 hours, cellular ATP levels 
were determined using an ATP assay kit (Roche, Indianapolis, IN, USA) following the 
manufacturer’s protocol. Values were normalized to the cell counts. This experiment was 
repeated twice yielding similar observations.   
Cytotoxic assays: 
Cells were seeded at 5×103 in 96-well plates or at 2.5×105 in 12-well plates. Cells 
were treated for 72 hours after they attached. The MTT assay was used in 96-well plate 
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culture and trypan blue stain and counting were used for cells in 12-well plate culture. 
GraphPad Prism statistical software was used to calculate inhibitory concentration. 
These experiments were repeated three times with similar results. 
Quantitative real-time PCR: 
Cells were cultured in 60mm dishes for RNA extraction using Trizol (Life Technologies) 
and cDNA was prepared using Thermo Scientific Verso cDNA Kit following 
manufacturer’s protocol. RT-qPCR was performed using Roche FastStart Universal 
SYBR Green Master Mix (Roche) following the manufacturer’s protocol. These 
experiments were repeated three times with similar results. 
Growth Kinetics: 
To determine growth kinetics, 2.5×105 cells were seeded in 12-well tissue culture 
plates in control and low pH media. These cells were trypsinized at 24, 48, 72, and 96 
hours after the cells attached to the plate. If cells received treatment, this was re-applied 
every 24 hours. Once collected, cells were stained with trypan blue (Gibco) and counted 
using BioRad TC20 automated cell counter. These experiments were repeated three 
times with similar results. 
Data analysis: 
Student’s t-test was used to compare data between two groups. Two-way 
ANOVA was used to compare data from multiple groups defined by two variables. When 
results are significant, post-hoc analyses with Bonferroni method for multiple 
comparisons were conducted. All data analyses were conducted using Graphpad Prism 
5. 
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Results 
PDAC cell growth is diminished in low pH conditions 
Intracellular pH value is known to have a significant role in conveying proliferation 
and death signals [57]. For example, it has been observed that proliferating cells require 
an intracellular alkaline pH value greater than 7.2, to allow for growth-factor stimulated 
cells to enter the S-phase of the cell cycle at a faster rate, and proceed to the G2 and M 
phases more rapidly [177, 178]. Furthermore, a higher pH is known to suppress mitotic 
arrest due to activated DNA damage checkpoints; therefore, maintaining an alkaline 
intracellular pH enhances bypassing of cell cycle checkpoints allowing cells to have 
unrestricted proliferation [179, 180]. While intracellular acidic pH promotes pro-apoptotic 
BAX by enhancing conformational changes that facilitate mitochondrial insertion thereby 
increasing pore formation allowing increased permeability to the mitochondria and 
release of pro-apoptotic proteins such as cytochrome-c into the cytosolic compartment 
[181]. PDAC cells in culture (pH 7.4) exhibit the Warburg Effect [93]. Hence, we 
investigated whether chronic low ph of extracellular milieu would have an effect on cell 
growth. To address this question we determined the growth kinetics of PDAC cell lines 
(S2-013 and Capan-1) in various acidic pH values of tumors reported in the literature 
and identified that the pH value between 6.9-7.0 resulted in significant growth reduction 
when compared to the physiological pH (Fig. 1A). To determine if reduced growth in low 
pH is due to reduced clonogenicity we conducted colony formation assays and identified 
that cells in low pH culture have reduced clonogenicity compared to the cells that are 
cultured in control pH (Fig. 1B). Subsequently, we synchronized growth of cells cultured 
in control and low pH conditions with a double thymidine block and released them for 20 
hours before collecting them to be fixed and stained with propidium iodide, to determine 
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DNA content using flow cytometry. We identified that cells in the G1/G0 phases are 
significantly increased in low pH culture; we further observed decreased percentage of 
cells in the S and M phases (Fig. 1C). This data indicates cell cycle arrest in the G1/S 
transition in PDAC cells in the low pH environment that results in reduced rate in cell 
cycle progression and growth. 
Reduced glucose uptake and metabolism in low pH conditions 
Rapid growth and progression through the cell cycle is associated with up-
regulation of glycolysis. We thus performed [3H] glucose uptake assays and determined 
that cells in low pH culture have a significant reduction in glucose uptake compared to 
cells in control pH (Fig. 2A). We also conducted a lactate release assay and found that 
in chronic low pH exposure there is a significant reduction in lactate release (Fig. 2B). To 
determine if the reduction in glucose uptake and lactate release was due to a decrease 
in glycolysis, we isolated polar metabolites from cells in both control and low pH culture, 
and conducted liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS)-
based metabolomics analyses. Our LCMS analysis demonstrated that glycolysis 
metabolites are significantly reduced in low pH (Fig. 2C). Collectively, our data 
demonstrates a clear departure from the classic Warburg Effect metabolic phenotype.  
Increased oxidative phosphorylation in low pH conditions 
 Our metabolomics data also demonstrated that cells in low pH have active 
mitochondrial metabolism (Fig. 3A). As a parallel nutrient source, glutamine is essential 
in oxidative metabolism because it can be metabolized to generate alpha-ketoglutarate 
and enter the TCA cycle [170]. To evaluate if alterations in glutamine metabolism 
complement for the reduced glucose metabolism, we next evaluated glutamine uptake. 
We supplemented cells with [3H] glutamine and observed that cells in chronic low ph 
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stress have a significant increase in glutamine uptake (Fig. 3B). To determine if the 
increase in glutamine uptake had an effect on oxidative metabolism and ATP generation 
we collected cell lysates from cells cultured in low pH and control pH conditions, and 
observed that cells in low pH generate significantly more ATP than cells in control pH 
culture (Fig. 3C). Next, we treated both control and low pH cells with oligomycin, an 
inhibitor of complex V (ATP synthase) in the electron transport chain, which acts by 
blocking the channel formed by the F0 complex of ATP synthase inhibiting H+ movement 
down its concentration gradient, thereby preventing ATP synthesis [182]. Treatment of 
cells in control and low pH with oligomycin showed that cells in low pH are much more 
sensitive than cells in control pH, by several orders of magnitude (Fig. 3D). These data 
demonstrate that chronic low ph influences a metabolic shift that enhances glutamine 
metabolism over glucose metabolism resulting in a change in ATP generation from 
substrate level phosphorylation to oxidative phosphorylation.  
Increased glutamine metabolism in low pH conditions 
Metabolomic analysis identified a significant increase in the levels of metabolites 
involved in non-canonical glutamine metabolism in S2-013 and Capan1 cells cultured 
under chronic low pH (Fig. 4A). Furthermore, RT-qPCR analysis demonstrated 
increased mRNA levels of genes involved in non-canonical anaplerotic glutamine 
metabolism under chronic low ph conditions (Fig. 4B). To further validate these 
observations, cells in control and low pH were treated with metabolic inhibitors targeting 
canonical and non-canonical glutamine metabolism. Cells were treated with 
aminooxiacetic acid (AOA) and epigallocatechin gallate (EGCG) to inhibit the 
transaminase enzymes (GOT1, GOT2) and GLUD1, respectively. We determined that 
the cells in low pH were at least an order of magnitude more sensitive to AOA treatment 
(Fig. 4C); however, the inhibitory concentration of EGCG was only modestly different in 
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control and low pH (Fig. 4D). Hence, our data indicate that cells with chronic low ph 
develop a metabolic phenotype that is highly dependent on anaplerotic glutamine 
metabolism, as demonstrated by increased metabolite levels, enzyme transcription, and 
increased sensitivity to a transaminase inhibitor (Fig. 4E). 
GOT1 counters ROS production under low pH conditions 
 Anaplerotic glutamine metabolism can provide the fuel for proliferation by 
generating ATP through the TCA cycle, generation of NADPH for redox reactions, and 
production of NEAAs used in protein biosynthesis [108, 168, 170]. Thus, we speculated 
that up-regulation of anaplerotic glutamine metabolism is required for maintenance of 
cellular homeostasis during stress induced by chronic low ph. Based on our 
metabolomics analysis, we predict that due to the low glycolytic rate observed in chronic 
low ph the flow of metabolites into the pentose phosphate pathway for generation of 
glycolysis derived NADPH is reduced. Therefore, anaplerotic glutamine metabolism is 
essential for ROS suppression in low pH. Furthermore, we identified increased GOT1 
levels in low pH and as previously stated GOT1 is the first enzyme in the glutamine 
anaplerotic pathway and its metabolic reaction allows glutamate-derived aspartate to be 
metabolized and generate NADPH for ROS suppression. To determine this, we 
generated stable knockdowns of GOT1 (Fig. 5A). Recent reports have shown that GOT1 
and glutamine reprogramming are increased in PDAC [183]. Of note, under control pH 
conditions, we observed minimal growth inhibition in GOT1 knockdown cells, compared 
to control shRNA-transfected cells. However, GOT1 knockdown cells demonstrate 
significant growth inhibition compared to control cells in low pH (Fig. 5B-C). The most 
prominent PDAC phenotype we have observed in low pH culture is the increase in 
oxidative metabolism, which can lead to a substantial increase in reactive oxygen 
species (ROS). ROS are diverse in their functions, and depending on their concentration 
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they may have different outcomes [184]. For instance, low concentrations of ROS may 
induce proliferative signaling and activation of survival pathways, but at high levels, there 
is ROS-induced pathology due to damages in DNA, proteins, and lipids, as a result, 
oxidative damage may result in growth inhibition, senescence, and cell death [185-189]. 
We measured ROS levels (HO, 1/2 O2, H2O2) using 2,7-dichlorofluorescin diacetate 
(DCFDA) and found that GOT1 knockdown cells in low pH have significantly higher 
levels of ROS than control cells in alkaline pH (Fig. 5D). To further validate these 
observations we measured intrinsic ROS levels and ROS levels induced after hydrogen 
peroxide supplementation using DCFDA. We utilized the ROS-insensitive dye 5(6)-
Carboxy-2’,7’-dichlorofluorescin diacetate (CDCFDA) as a negative control and H2O2 as 
a positive control (Fig. 5E). Of note, the inhibition of non-canonical glutamine metabolism 
by GOT1 knockdown results in increased ROS levels, which are further increased in low 
pH culture conditions. We conclude that cells in low pH generate more ROS that are 
increased upon inhibition of anaplerotic glutamine metabolism due to decreased GOT1.  
Cancer cells are known to have increased expression of enzymes that suppress 
high ROS levels to prevent senescence and/or apoptosis [190-192]. ROS production can 
be increased by oxidation of nicotinamide dinucleotide phosphate (NADPH) by NADPH 
oxidase enzymes (NOX). It can also be increased through mitochondrial electron 
leakage, generating increased superoxide levels [151]. Superoxide levels are reduced 
by superoxide dismutases (SOD) that can combine superoxide radicals with water to 
produce hydrogen peroxide (H2O2), which in turn is capable of initiating redox biology by 
oxidizing cysteine residues of proteins and initiate signaling events [193]. By LC-MS/MS-
based quantification, we analyzed the redox status of the most abundant antioxidant 
molecules NADPH and GSH. Our analysis revealed that the NADP/NADPH ratio is very 
similar in both alkaline and acidic pH conditions, but the glutathione disulfide/glutathione 
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(GSSG/GSH) is much higher in cells cultured in low pH (Fig. 5F). These data indicate 
that the antioxidative capacity of GSH is lesser in low pH. In rapidly proliferating cells, 
NADPH is mainly produced from glycolysis in the pentose phosphate pathway, with 
smaller contributions from isocitrate dehydrogenase and malic enzyme [151]. Our RT-
qPCR analysis of the enzymes involved in anaplerotic glutamine metabolism showed 
that the malic enzymes ME1 and ME2 have a significant increase in transcription in low 
pH (Fig. 4B). We also performed RT-qPCR of the enzymes involved in antioxidant 
metabolism, and identified a very prominent increase in the expression levels of NOX1, 
NOX2, and NOX3 in GOT1 knockdown cells cultured in low pH, in comparison to control 
shRNA-transfected cells (Fig. 5G-I). Of note, these transcript level differences are not 
compensated by an increase in SOD1/SOD2 mRNA levels (Fig. 5J-K). Therefore, cells 
with GOT1 knockdown are unable to withstand low pH microenvironment due to 
generation of cytotoxic ROS levels.  
Oxaloacetate can rescue GOT1 knockdown cells under low pH 
 The reaction carried out by GOT1 uses aspartate as a substrate and converts it 
into oxaloacetate (OAA) [108]. Hence, we supplemented knockdown cells in low pH with 
oxaloacetate to re-establish anaplerotic glutamine metabolism and allow knockdown 
cells to suppress ROS. As a positive control of ROS suppression, we supplemented 
cells with N-acetyl cysteine (NAC; a ROS quencher), and aspartate and alanine, the 
non-essential amino acid products of this pathway, were used as negative controls. The 
growth of cells in low pH was compared to the cells supplemented with 3mM of NAC, 
2mM of OAA, or 0.1mM of NEAA for 96 hours. Our results indicate that both NAC and 
OAA enhance cell growth and colony formation in low pH under GOT1 knockdown 
conditions, while supplementation with NEAA had no effect (Fig. 6A-B). To determine if 
OAA treatment has the same effect as NAC in decreasing ROS levels we supplemented 
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cells with OAA, NAC, and H2O2 to subsequently measure ROS levels using DCFDA. Our 
results showed that only the cells with GOT1 knockdown cultured in low pH have 
decreased ROS levels when supplemented with 2mM of OAA (6C). Thus, our data 
indicates that inhibition of anaplerotic glutamine metabolism by removing GOT1 results 
in increased ROS levels and the addition of OAA rescues cell growth by resuming this 
metabolic pathway.  
Discussion 
Acidification of the tumor microenvironment is a common feature of PDAC (and 
of most epithelial tumors). Understanding the metabolic changes that PDAC cells 
undergo due to acidosis stress is extremely important in designing more effective 
treatments. Our metabolomic analysis shows that cells in low pH depart from Warburg 
effect metabolism, and that they increase anaplerotic glutamine metabolism to allow 
cells to generate vast amounts of ATP, which in turn allows for maintaining cellular 
homeostasis during acidosis stress. We demonstrate for the first time that anaplerotic 
glutamine metabolism-mediated countering of ROS levels serves as the survival 
mechanism for pancreatic cancer cells under chronic low ph.   
Glucose and glutamine are the primary nutrients for cancer cells; however, only 
glutamine can provide both carbon and nitrogen [194]. Indeed, glutamine is an important 
growth signal [195]. Furthermore, glutamine can be metabolized into products such as 
nucleic acids, glucosamine, and NEEAs [195]. Based on our experiments to determine 
cell growth in low pH and rescue of cell survival with oxaloacetate upon GOT1 depletion, 
we believe that utilization of glutamine under low pH stress is not meant to induce 
growth signals or biosynthesis of macromolecules instead it is used for energy 
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biosynthesis to maintain homeostasis through moderation of high ROS levels stressing 
the cells.   
Recent studies have demonstrated the advantages of non-canonical glutamine 
metabolism over the canonical pathway. In the study conducted by Coloff et al, it was 
demonstrated proliferating cells could take advantage of metabolism through the 
transaminase enzymes, whereas, quiescent epithelial cells have decreased 
transaminase expression; furthermore, glutamine metabolism is diverted to GLUD 
diminishing the biosynthetic potential of glutamine metabolism [168]. Similarly, in the 
study by Son et al. it was demonstrated that oncogenic KRAS plays a significant role in 
glutamine metabolic reprogramming in PDAC through the transcriptional upregulation of 
GOT1 and inhibition of GLUD1 expression [108]. Furthermore, this and other studies 
reveal the role of non-canonical anaplerotic glutamine metabolism in the generation of 
NADPH and possibly ROS regulation through coupling with other redox balance 
pathways such as glutathione synthesis [108, 196]. Here, we have shown that PDAC 
cells have the potential to reprogram metabolic pathways allowing them to maintain 
homeostasis in acidosis stress conditions.  
 In our studies, the increase of ROS levels is primarily due to leakage in 
mitochondrial superoxides from up-regulation of oxidative metabolism during low pH 
stress and also from up-regulation in the transcription of NADPH oxidases. For this 
reason, PDAC cells develop increased ROS levels that result in reduced proliferation 
during low pH stress. Furthermore, we find that inhibition of anaplerotic glutamine 
metabolism results in an increase in ROS levels and a further reduction in proliferation 
(Fig 5-6). Glutamine metabolism has the capacity of generating carbon, nitrogenous 
sources, and NADPH for redox balance [108, 168]. Since various studies have shown 
that there is increased expression of the transaminase enzymes driving non-canonical 
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glutamine metabolism in PDAC due to oncogenic KRAS, we predict that oncogenic 
KRAS plays a significant role in metabolic reprograming in low pH stress. The pH of the 
tumor microenvironment is heterogeneous while our experiments maintained a 
homogeneous pH value, there may be additional differences in the metabolic phenotype 
that correlates with the pH value inducing cellular stress we have seen here. Our 
findings may have implications to future therapeutic approaches since we have 
discovered the metabolic pathways the extracellular pH of the tumor microenvironment 
can modulate in pancreatic cancer cells. Our data may provide new targets to synergize 
with other known therapies for pancreatic cancer and increase therapeutic effectiveness 
against PDAC.  
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Chapter 2 Figures 
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Figure 1A. PDAC cell growth is inhibited with decrease in pH of DMEM medium. 
(A) Survival of S2-013 and Capan-1 PDAC cells cultured under conditions of varying pH 
of culture media by MTT assays. These growth curves show that cells are not viable in 
pH values bellow 7, which was then used to establish chronic low ph. Fig. 1A values 
were normalized to control pH 7.4 (physiological pH value) at 72 hours of growth. Error 
bars represent mean ± S.E.M. from at least three different samples. Two-way ANOVA 
with Bonferroni post-test analysis was used for Fig. 1A to compare growth in low pH 
versus physiological pH.  
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Figure 1B. PDAC cells have reduced clonogeneicity in chronic low pH. PDAC cell 
lines were adapted for 14 days to chronic low ph. Subsequently, these cells were sub-
cultured and a fraction was diluted to seed 200 cells in 6-well plate for 14 days in control 
pH (7.4) and low pH (7.0). Cell numbers were normalized to that of the control pH 7.4 
(physiological pH value). Error bars represent mean ± S.E.M. from at least three different 
samples. A two-tailed Student's t-test was used to compare low pH and control pH with 
p-values *p < 0.05, **p < 0.01, and ***p < 0.001.  
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Figure 1C. Chronic low pH expossure decreases cell cycle progression of PDAC 
cells. Cell cycle analysis of S2-013 cells in control and low pH shows a significant 
increase of population in G1/G0 indicating reduced clonogeneic rate. Cell numbers were 
normalized to that of the control pH 7.4 (physiological pH value). Error bars represent 
mean ± S.E.M. from at least three different samples. A two-tailed Student's t-test was 
used to compare low pH and control pH with p-values *p < 0.05, **p < 0.01, and ***p < 
0.001.  
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Figure 2A and 2B. PDAC cells in chronic low pH exposure shows a significant 
decrease in hallmarks of Warburg effect metabolism. Compared to control cells, 
cells cultured in chronic low pH have a significant decrease in glucose and lactate 
release both of which are the quintessential hallmarks of Warburg effect metabolism as 
shown by (A) 3H-glucose uptake and (B) lactate release using colorimetric assay and 
LC/MS/MS analysis of extracellular metabolite extracts. Data is normalized to that of the 
cells at control pH (7.4). Error bars represent mean ± S.E.M. from at least three different 
replicates. A two-tailed Student's t-test was conducted to compare uptake/release in low 
pH relative to control pH with p-values *p < 0.05, **p < 0.01, ***p < 0.001.  
	 90	
		
Figure 2C. PDAC cells in chronic low pH exposure shows a significant decrease in 
glycolysis. Polar metabolites were extracted from S2-013 and Capan-1 cells cultured in 
control and low pH. LC/MS/MS-based metabolomics was used to quantify glycolysis 
metabolites showing a significant decrease in glycolysis metabolic flux in low pH culture 
conditions.	
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Figure 2C. TCA cycle metabolic flux is maintained in chronic low pH. Polar 
metabolites were extracted from S2-013 and Capan-1 cells cultured in control and low 
pH. LC/MS/MS-based metabolomics was used to quantify TCA cycle metabolites 
showing that unlike glycolysis TCA metabolism is not down regulated. Data in bar charts 
is normalized to the values for the control pH (7.4). Error bars represent mean ± S.E.M. 
from at least three different samples. A two-tailed Student's t-test to represent this data 
with p-values *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 3B, 3C. PDAC cells in chronic low ph show a significant increase of 
glutaminolysis. Compared to control pH, PDAC cells in chronic low ph show a 
significant increase in glutamine uptake and intracellular ATP levels as shown by 3H-
glutamine uptake and bioluminescent assay to determine ATP levels in cell lysates. 
Error bars represent mean ± S.E.M. from at least three different samples. A two-tailed 
Student's t-test was conducted to compare these data sets with p-values *p < 0.05, **p < 
0.01, ***p < 0.001. 
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Figure 3D. PDAC cells in chronic low ph increase use of oxidative 
phosphorylation. Cells cultured in low pH show a marked decrease in survival upon 
oligomycin treatment. Oligomycin inhibits complex V of the electron transport chain.  
	 94	
		
Figure 4 A. Metabolic flux through non-canonical anaplerotic glutamine 
metabolism is enhanced in chronic low ph. (A) LC/MS/MS-based metabolomic 
analysis of non-canonical glutamine metabolism in control (7.4) and low pH (7.0) culture 
conditions shows increased metabolic flux through the glutamate transaminase-driven 
pathway. Data in bar charts is normalized to the values for the control pH (7.4). Error 
bars represent mean ± S.E.M. from at least three different replicates. A two-tailed 
Student's t-test was conducted to compare control versus low pH in Fig. 4A and B with 
p-values *p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure 4 B. Transcription of enzyme mediators of non-canonical anaplerotic 
glutamine metabolism is increased chronic low ph. Quantitative real-time PCR 
analysis of genes coding for enzymes involved in non-canonical glutamine metabolism in 
cells cultured under control and low pH. Data shows an increase of transaminase 
enzymes and malic enzyme both of which are mediators of non-canonical glutamine 
metabolism. Data in bar charts is normalized to the values for the control pH (7.4). Error 
bars represent mean ± S.E.M. from at least three different replicates. A two tailed 
Student's t-test was conducted to compare control versus low pH in Fig. 4A and B with 
p-values *p < 0.05, **p < 0.01, ***p < 0.001.  	
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Figure 4C and 4D. PDAC cells cultured in low pH conditions are more sensitive to 
inhibition of glutamine metabolism. Treatment of S2-013 and Capan-1 cells to 
treatment with aminooxyacetic acid (AOA; C) and to epicogallocatechin gallate (EGCG; 
D) in control and low pH conditions shows increased sensitivity to glutamine metabolism. 
However, cells in low pH are more sensitive to inhibition of the anapleurotc pathway.  		
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Figure 4E. PDAC cells cultured in low pH conditions are more sensitive to 
inhibition of glutamine metabolism. Figure 4E shows a schematic illustration of 
potential metabolite flow of glutamine in low pH culture conditions. The bold arrows 
denote the metabolic flux of glutamine through the non-canonical pathway. Glutamine is 
metabolized by glutamate synthase (GLS) and converted to glutamate, which is then 
metabolized by glutamate dehydrogenase (GLS1) and/or glutamic oxaloacetic 
transaminase 2 (GOT2). Subsequently, aspartate is metablized by glutamic oxaloacetic 
transaminase 1 (GOT1) to oxaloacetate, which is converted to malate and then to 
pyruvate by the malic enzymes. GOT1 expression is enhanced by oncogenic KRAS and 
Malic Enzymes are critical fro NADPH production for redox homeostasis.   
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Figure 5A, 5B, and 5C. Knockdown of GOT1 inhibits growth of PDAC cells in low 
pH. (A) Western blotting to confirm the knockdown levels of GOT1 in S2-013 with two 
independent targets by utilizing lentiviral delivery. Cell growth of GOT1 knockdown and 
scrambled-control (shScr) cells in control pH (B) and low pH (C). GOT-1 knockdown 
significantly reduces cell growth in both culture conditions, but cells in low pH are 
severely impaired. A two-way ANOVA analysis, followed by Bonferroni posttests, was 
conducted to compare growth curves with p-values *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 5D and 5E. GOT1 depletion further increases intracellular ROS levels in low 
pH culture. Fig. 5D shows measurement of intracellular ROS using carboxy-H2DCFDA 
in control and low pH showing that ROS levels are higher in low pH culture. 
Furthermore, GOT1 knockdown leads to increase ROS levels in both control in low pH, 
but increase of intracellular ROS is much greater in low pH knockdown cells. Fig. 5E 
shows the measurement of intracellular ROS of cells in low pH by staining with carboxy-
H2DCFDA (DCFDA) and staining with CDCFDA, a ROS-insensitive dye. The ROS-
insensitive compound was used to show fluorescence was not an artifact of cell culture 
using hydrogen peroxide treatment as a positive control as it induces ROS. The 
experiment shows that CDCF stain does not detect ROS levels.  Data in bar charts is 
normalized to the values for the control pH (7.4). A two-way ANOVA analysis, followed 
by Bonferroni posttests, was conducted to compare different treatments represented on 
all the other panels with p-values *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 5F-5K. GOT1-mediated anaplerotic glutamine metabolism produces NADPH for 
ROS homeostasis. Fig. 5F LC/MS/MS measurement of NADP/NADPH and GSSG/GSH ratios in 
control and low pH culture shows similar NADP/NADPH ratio, but the GSSG/GSH ratio is higher 
in low pH culture indicating deregulation in NADPH mediated ROS suppression. Figures G to K 
show quantitative real-time PCR analysis of genes coding for enzymes involved in ROS 
regulation through oxidation of NADPH. Here it is observed that in low pH transcription of NADPH 
oxidases (NOX) increases. NOX enzymes oxidize NADPH producing superoxide as a by-product 
and super oxide dismutase (SOD) removes super oxides by combining it with protons and 
producing hydrogen peroxide, which is then removed by reduced glutathione (GSSG-ox or GSH-
red) through GSH peroxidase or catalase, which is unchanged in low pH (data not shown). This 
data implies ROS suppression occurs is of high priority in low pH.  Data in bar charts is 
normalized to the values for the control pH (7.4). A two-way ANOVA analysis, followed by 
Bonferroni posttests, was conducted to compare different treatments represented on all panels 
with p-values *p < 0.05, **p < 0.01, ***p < 0.001 
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Fig. 6. Non-canonical glutamine metabolism regulates growth in chronic low ph. 
Growth kinetics of scrambled control, and GOT1 knockdown cells cultured in low pH 
media supplemented with N-acetyl cysteine (NAC), non-essential amino acids (NEAA), 
or oxaloacetate (OAA). OAA is the product of the reaction carried by GOT1. This 
experiment shows that growth is of knockdown cells in low pH is rescued by 
supplementing OAA and ROS-quencher NAC suggesting the significance of metabolic 
flux through GOT1 for ROS homeostasis. A two-way ANOVA analysis, followed by 
Bonferroni post-tests, was conducted to compare different treatments with p-value *p < 
0.05, **p < 0.01, ***p < 0.001. 
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Figure 6B and 6C. Non-canonical glutamine metabolism regulates ROS levels in 
chronic low ph. Fig. 6B colony formation of control and GOT1 knockdown cells 
supplemented with NAC and OAA shows rescue of clonogeneicity upon pathway rescue 
(OAA) and ROS quenching (NAC). Fig 6C shows suppression of intracellular ROS levels 
in control and GOT1 knockdown cells supplemented with OAA and NAC, using H2O2 as 
a positive control. Data in bar charts is normalized to the values for untreated scrambled 
control. Error bars represent mean ± S.E.M. from at least three different replicates. A 
two-way ANOVA analysis, followed by Bonferroni post-tests, was conducted to compare 
different treatments with p-value *p < 0.05, **p < 0.01, ***p < 0.001. 
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Chapter 3 
Discussion: 
Conclusions & Future Directions 
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Summary of Work 
Summary of Thesis: 
Upon malignant transformation, PDAC cells modify their environment through 
activation of PSCs leading to the desmoplasia and the collapse of normal tissue 
vasculature that is replaced by the disorganized tumor vasculature. These changes in 
TME favor growth of cancer cells as the hypoxic microenvironment activates HIF 
inducing metabolic reprogramming that facilitates growth through up-regulation of 
glycolysis. Similarly, oncogenes such as KRAS promote increased uptake of glucose 
and glutamine, which are metabolized to produce energy, biomass, and co-factors for 
redox reactions. Collectively, HIF activation and oncogenes cause Warburg effect 
metabolism that is characterized by increased glucose uptake and its conversion to 
lactate and protons, glutamine can be converted to lactate as well. The increased 
metabolic rate of cancer cells results in accumulation of protons in the TME. 
Interestingly, consistent measurements of intracellular and extracellular pH of growing 
cancer cells show that pHi is alkaline and pHe is acidic. Decrease in pHi has been 
shown to result in growth inhibition and apoptosis, while acidic pHe has been shown to 
promote acidosis through activation of extracellular proteases that degrade ECM. 
Based on these observations, the role of acidosis in carcinogenesis is being redefined 
from a collateral effect of up-regulated metabolism to a hallmark of cancer.  
However, the disorganized vasculature of tumors becomes an inefficient method to 
vent metabolic acids from the TME. This creates a paradox as cancer cells require a 
high metabolic rate to proliferate, but further disparity in the proton gradient between 
the cytosol and the extracellular space of cells, which will prevent efficient proton 
efflux from the cytosolic compartment thereby lowering pHi. Cancer cells cannot 
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withstand cytosol acidification because excess protons will affect the ionization of 
protonatable residues of amino acids in proteins thereby affecting their normal 
function. Thus, maintenance of the aforementioned pH gradient is critical for survival 
of cancer cells. For this reason cancer cells have developed complex mechanisms to 
regulate pH through active transport of charged molecules across the plasma 
membrane. Based on the pH challenge PDAC cells experience in the TME, I 
hypothesized that further survival of PDAC cells is through selection of mechanisms 
allowing cells to regulate metabolism or reprogram their metabolism in order to satisfy 
pH homeostasis. To this end I replicated chronic acidification similar to tumor 
conditions and demonstrated that chronic low ph causes growth inhibition likely due to 
increased ROS levels. In this low pHe conditions, it was demonstrated that cells 
survive by reprogramming their metabolism by enhancement of anapleurotic 
glutamine metabolism at the expense of reducing glycolytic rate. The pathway is 
enhanced by oncogenic KRAS expression and it serves the purpose of generating 
energy for cellular homeostasis, as well as, providing the cells with NADPH for redox 
control. 
Conclusions based on experimental evidence and extant literature: 
  In vivo venting of protons depends on the proximity of cells to blood vessels 
where the blood buffer system can remove excess protons. Therefore, the TME of 
PDAC will contain cells far away from the blood vessel where cells survive by 
activation of HIF response, which will cause an increase in dumping of protons onto 
the extracellular space. Absolute oxygen deprivation will kill the cells; thus, cells must 
be selected to move to gain oxygen access. At the same time, cells in the most 
hypoxic or oxygen deprived region will secrete excess protons into the extracellular 
space and the slow movement of protons toward the blood vessel will create the most 
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acidic region of the tumor. Cells in the most acidic part of the tumor will have to 
reprogram their metabolism in order to produce less protons, as their capacity to vent 
protons from the cytosol will be reduced by the increased extracellular proton 
gradient. Thus, a metabolic switch in which production of CO2 is increased will be 
more favorable because CO2 can passively diffuse across the plasma membrane. 
This metabolic shift is likely supported by several mechanisms, including the 
expression of nuclear respiratory factor 1, NRF1, that enhances mitochondria 
function, increase in expression of the isoform of cytochrome c oxidase subunit 4 
isoform 1 change to isoform 2, COX4I1 to COX4I2, and mitochondria cristae remodeling 
to optimize ETC efficacy in low oxygen conditions [197, 198]. In this way, cells that can 
adapt to acidosis of TME can survive by generating CO2 instead of protons. Cells that 
are more proximal to blood vessels, are driven to grow by increased expression of 
oncogenes, loss of tumor suppressors, and abundance of nutrients. Thus, this cell 
population experiences less selective pressure, but at the same time it bears the 
cancer phenotype of uncontrolled growth that will lead to continuous acidification of 
extracellular space. Thus, the cells closer to the nutrients exhibit Warburg effect and 
their release of protons into the TME will decrease venting of protons produced by 
cells further away from blood vessels. It is a common understanding that the most 
aggressive cells in PDAC tumors develop in the most hypoxic region, which is likely to 
be the most acidic as well [136]. Figure 1 summarizes these statements.  
Role of TME acidosis in carcinogenesis 
Metastasis 
In the past two decades the correlation between acidic TME and metastasis 
gained much needed interest leading to extensive studies of this relationship. Thus, it 
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has been shown that decreased pHe promotes invasiveness by enhancing cytoskeletal 
dynamics leading to modification of cancer cell polarization, as well as, increase in 
proteolytic activity of TAMs and fibroblasts, as well as, activating ECM proteases 
released by the cancer cells themselves [34, 199, 200]. Interestingly, the contrasting 
alkaline pHi promotes cytoskeleton remodeling by enhancing the activity of several 
acting binding proteins [201]. These observations were shown in vivo using intravital 
microscopy by monitoring HCT-116 cells, which showed that the lowest pHe regions of 
the tumor underwent more cytoskeleton remodeling and had the highest expression of 
NHE1 in order to maintain alkaline pHi [201]. Activation of proteases by acidic pHe was 
demonstrated to increase angiogenesis by liberating pro-angiogenic factors trapped in 
ECM—at the same time this promoted metastasis of cancer cells by clearing path to the 
vasculature [202]. Another feature of TME acidosis that has gained interest over the 
years is the increase of stem cell markers in cells cultured in acidic pH medium [203]. 
Acid-induced stemness is not limited to cancer cells, as it has been demonstrated in 
osteosarcoma and melanoma that the low pH of the TME increases the population of 
mesenchymal stem cells, which contribute to tumor growth by secreting pro-tumorigenic 
factors [204]. Based on these observations, the process of carcinogenesis requires 
acidification of the TME, as it will continue selecting the most aggressive malignant 
phenotype. In addition passive CO2 and H+ venting of protons and active transport of 
protons, Gillies et al. demonstrated that the lysosme associated membrane protein 2, 
LAMP2, is critical for breast cancer tumorigenesis because it relocates to the plasma 
membrane to aid the process of TME acidification thereby enhancing metastasis [205]. 
These lines of experimental evidence highlight selection of acidic TME to further 
promote carcinogenesis.  
Acidosis induces autophagy 
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Autophagy is a regulated cellular process through which dispensable organelles 
and macromolecules are turned over for metabolic purposes within the same cell . 
Pancreatic cancer cells show elevated autophagy under basal conditions and its 
inhibition leads to increased ROS, elevated DNA damage, and oxidative metabolic 
defects associated with mitochondria dysfunction [206]. As a result, inhibition of 
autophagy results in significant growth inhibition of PDAC cell lines, orthotopic mouse 
models, and genetic ablation of autophagy results in prolong survival in animal models. 
These observations suggest that autophagy is a feature of PDAC carcinogenesis, unlike 
other cancer types where autophagy is a last resource survival mechanism upon 
therapy-induced stress. Interestingly, increase in autophagy markers was demonstrated 
upon acidosis stress in breast cancer cell line MDA-MB-231 this phenotype was 
reversed/diminished in vivo upon administration of sodium bicarbonate [207]. The role of 
autophagy in acidosis stress was further elucidated in melanoma cells, which were 
unable to survive acidic stress upon knockdown of ATG5, autophagy marker necessary 
for the processes to take place [208]. Further studies have elucidated the role of pHi 
acidification in inhibiting mTOR, which occurs by TSC complex acting as a pH sensor, 
protonation of residues inhibit its activation of mTOR, and by decrease in leucine uptake 
that activates mTOR mediated inhibition of autophagy [209, 210]. The role of mitophagy 
in acidosis may be just as essential for cell survival, as the mitochondria are critical for 
metabolic reprograming necessary to survive in low pH stress and functional 
mitochondria are required for metabolic reprogramming necessary to survive acidosis 
stress [211]. Similarly, functional autophagy requires the acidification of autolysosomes 
that achieve it through expression of V-ATPases allowing them to remove protons from 
the cytosol into the lysosome vesicle [212]. The transformation of autophagy from a 
tumor suppressive mechanism in normal cells into a pro-tumor mechanism in PDAC may 
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be a consequence of cancer cell pH dynamics. These observations further highlight the 
role of acidosis in PDAC carcinogenesis. 
Acidosis of TME leads to immune suppression 
Several lines of evidence show that acidification of the TME affects the anti-
tumor immune response as exposure to lactate and protons decreases T-cell production 
of IL-2, IFNγ, perforin, and granzyme B, as well as, inhibiting TNF release by monocytes 
[213, 214]. Metabolomic analysis showed that low pH abrogates glycolysis in T-cells 
causing inhibition of cytokine synthesis. Similarly, it has been shown that the  decreased 
immune response due to lowering pHi prevents increased expression of nuclear factor of 
activated T-cells, NFAT, in NK cells and T-cells [215]. Studies showing the relationship 
between the metabolic rate of cancer cells and its effects on T-cells in the TME showed 
that T-cells deprived of glycolysis were unable to regulate NFAT-Ca2+ signaling to elicit 
an immune response [216]. This was denoted by the low levels of PEP that were 
corrected by overexpression of PEP carboxykinase, PCK, which allowed the cells to 
utilize oxaloacetate to make PEP and re-establish glycolysis [216]. Similar observations 
have been made upon ablation of LDHA, resulting in lower TME levels of protons and 
lactate. Thus, cancer cells in the TME inhibit immune response by outcompeting immune 
cells for nutrients and by exposing them to a low pHe, which induces metabolic 
reprogramming to oxidative phosphorylation thereby inhibiting glycolysis-NFAT signaling 
that allows for production of cytokines. These observations further highlight the 
dependency of carcinogenesis in TME acidosis.  
pH Sensing 
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It is estimated that the acid load in the extracellular space of tumors is up to 10 
times higher than in the cytosolic compartment and can lead to pH change of up to 1 pH 
unit [217]. As I have previously described, excess protons are vented through the 
bicarbonate buffer system aided by blood and kidneys. However, it is predicted that long 
venting distances of more than 50µm will result in chronic low ph [217]. The most 
extensively studied pH sensors in the plasma membrane are G-protein coupled 
receptors, GPCRs, GPR4, OGR1, TDAG8, and G2A [218]. GPR4 stimulated by acidosis 
has been reported to activate the Gs G12/13 pathways that increase cAMP levels and 
activate Rho-Gef pathways for induction of cell migration respectively [219]. Low levels 
of GPR4 in mouse models of melanoma results in impaired tumor growth and 
impairment of angiogenesis [218, 220]. Overexpression of OGR1 has been shown to 
inhibit metastasis in PC3 prostate cancer cells and in HEY ovarian cancer cells by 
increasing adhesion to several ECM proteins [218, 220, 221]. TDAG8 has been shown 
to increase tumor growth in Lewis lung carcinoma with similar findings shown in animal 
models using NCI-H460 non-small cell lung cancer cell line with knockdown of TDAG8 
showing reduced survival in acidic conditions of tumor [219, 222]. TDAG8 activation by 
acidosis has been demonstrated to inhibit apoptosis upon nutrient starvation and its 
overexpression leads to transformation of mammary epithelial cells in vitro [219, 222]. 
Interestingly, in lymphoma high levels of TDAG8 has been shown to inhibit c-Myc 
expression thereby showing the ability of pH sensing to affect master regulators of 
metabolism [222]. G2A signaling is known to affect pH growth by inhabiting G2/M cell 
cycle progression resulting in mitosis inhibition [218]. Understanding the mechanisms of 
pH sensors will provide better insight into the molecular basis of pH-dependent survival 
of cancer cells in acidic TME by allowing us to understand their behavior in acidosis and 
eventually identify new diagnostics and therapeutics. 
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Although pH affects many cellular processes, one of the most sensitive systems 
in the cells is the actin cytoskeleton, which through its assembly and disassembly it 
determines vesicle trafficking, contraction, migration, invasion, and metastasis [57]. 
Interestingly, de novo trafficking assembly requires alkaline intracellular pH this process 
is greatly affected by decreasing the pHi. This highlights the significance of alkaline pHi 
as the cells will cease a lot homeostatic functions performed by the cytoskeleton if the 
pH drops. For example, cofilin requires the de-phosphorylation of a N-terminal serine 
and the deprotonation of a C-terminal histidine residue to de-polymerize filamentous F-
actin and begin the process of de novo actin polymerization [223]. Thus, in cell trafficking 
cells need a higher cytosolic pH to re-assemble and dis-assemble actin filaments. 
Similarly, it has been demonstrated that the leading edge of focal adhesions in migrating 
cells has a higher pHi this process is mediated by talin binding to F-actin in focal 
adhesions and that talin binding of F-actin filaments decreases if pHi drops bellow 7.2 
[223]. This is due to protonation of amino acids that cause a conformational change in 
talin that prevents interatcition with F-actin filaments. Interestingly, binding of cofilin and 
GEFs with plextrin-homology domains to phosphoinositides has been shown to be pH 
dependent [143, 223]. A common feature of phosphoinositide recognition domains is that 
at lease one histidine is contained within the recognition domain this has not been 
shown experimentally, but proteins with this domain may be pH sensitive for membrane 
localization [143]. Thus, understanding the significance of pH-dependent histidine 
switches can help to understand pH dependent cytoskeleton function.   
Targeting Phi Regulation For Therapy 
TME acidosis creates a challenge in cancer therapy 
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Neutral molecules can pass freely through the plasma membrane, but the 
passage of charged compounds depends on extracellular pH—this phenomenon is 
known as ion trapping [57]. The acidic TME of tumors is unfavorable to weak base 
chemotherapeutic agents such as paclitaxel because they will be protonated. Thus, it 
is estimated that if the pH difference between the intra and extra cellular 
compartments is 1 pH unit there will be a ten-fold negative difference in weak base 
concentration in the cytosol [224]. Conversely, the more acidic chemotherapeutic 
agents such as cisplatin will localize to the alkaline intracellular environment of cells. 
These phenomena calls for intervention through proton pump inhibitors in order to 
control extracellular pH and predict better delivery of therapeutic agents. 
Neutralization of pHe using systemic buffers such as NaHCO3 has been proposed in 
efforts to identify which therapeutic modalities to take advantage of TME 
neutralization [225]. Indeed, bicarbonate treatment in hepatocellular carcinoma 
increases the efficacy of weak base chemotherapeutic agents [226]. Interestingly, this 
approach does not affect growth of the primary tumor, but it has been observed to 
reduce metastasis in animal models. Furthermore, bicarbonate treatment has also led 
to improved immunotherapy response by increasing response to anti-PD1 and anti-
CTLA4 in melanoma mouse models [227]. The immunotherapy response can also be 
improved by inhibition of V-ATPases with proton pump inhibitors [228]. This 
observation was also shown in spontaneous mouse models of prostate 
adenocarcinoma where bicarbonate buffer treatment at 6-weeks of age, prior to tumor 
formation, resulted in lost of tumor formation and delay of tumor formation [229]. 
These studies highlight the significance of acidic pHe in carcinogenesis. Addition of 
exogenous buffers may have adverse physiological effects, as it will lead to systemic 
pathologic alkalosis [225]. Therefore, instead of targeting the pHe with buffers pH-
sensitive drug delivery systems have been developed. These molecules include 
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peptides, liposomes, micelles, and polymeric nanoparticles [224, 230]. pH-low-
insertion-peptides, pHLIPs, have been used to image PDAC tumor progression in vivo 
and ex vivo [231]. Thus, these molecules transport drugs to cancer cells through 
encapsulation or by chemical conjugation. These molecules work by having increased 
stability in physiological pH conditions and destabilizing or fusogenic in low pH 
environment [224, 230]. In this way, delivery to cancer cells in acidic TME is ensured 
and the viability of drugs is enhanced, as sequestration or inactivation during 
transport to tumor tissue will be diminished.     
Inhibition of cancer pHi regulation 
Proton-pump-inhibitors (PPI) are pro-drugs that are activated by low pH 
generating sulfenaminde therefore in the acidic gastric environment or in TME they 
become activated and covalently interact with sulfhydryl groups of cysteine residues 
of V-ATPases inhibiting their activity [232]. These compounds have reached advance 
clinical trials as they have demonstrated to suppress tumor growth in mouse models 
and prevent acid-induced therapy resistance caused by ion trapping effect. Another 
target for therapy, are the carbonic anhydrases, CA, particularly CAIX and CAXII that 
are overexpressed in many tumor types compared to normal tissue [233]. Indeed, 
CAIX positive staining is an indicator of poor prognosis in PDAC [234]. Interestingly, 
CAs distribution in tumor tissues show increased expression of CAIX in the tumor 
edge and CAXII occurring more in the tumor center [235]. These observations have 
led to the development of specific CA inhibitors, which have shown to be potent 
growth inhibitors of primary tumor and metastases evidenced in mouse models. For 
this reason antibodies and small molecule inhibitors of CAs are currently undergoing 
clinical trials [236]. Monocarboxylate transporters, MCTs, which conduct the inward 
and outward transport of protons and lactate from cytosol to extracellular space, are 
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also a reasonable therapeutic target [237]. The MCT1,2  inhibitor AXD3965 has 
shown potent anti-tumor effects in mouse models and is currently undergoing clinical 
trials [238]. More advantageously is the development of inhibitors for hypoxia specific 
MCT4; to this end, it has been reported that the drug diclofenac inhibits lactate efflux 
in cancer cells independently of inhibition with cyclooxygenase [239]. Another obvious 
target for disruption of pH regulation in cancer cells is the inhibition of sodium 
hydrogen exchanger, NHE1, but no clinical break through has been achieved. This 
has been shown by knockdown of NHE1 and treatment with NHE1 selective 
pharmacological inhibitors amiloride and cariporide that show extensive anti-cancer 
effects in vivo [240]. However, side effects of pharmacological inhibition of NHE1 
include myocardial infarction. Lastly, inhibition of sodium bicarbonate transporters, 
NBCs, is also a likely target to disrupt pH homeostasis. To his end, NBC specific 
compounds S0859 and S3705 have been used in vitro showing growth inhibition in 3D 
spheroid models and breast cancer cell lines [241]. 
Inhibition of pH regulation shows exceptional results in preventing further 
growth of tumors, but only a few compounds have reached clinical trials and they 
have delivered disappointing outcomes due to aberrant side effects. For example, 
MCT inhibitors are severely limited by the physiological role of the lactate shuttle in 
the brain or the overexpression of NHE1 in cardiac tissue [242, 243]. Another 
alternative is the dynamic nature of cancer, which upon selective pressure would lead 
to evolution of a compensatory mechanism with expression of different pH regulating 
proteins or reprogramming metabolism to produce less acids. To this end, new exiting 
data fro Grillo-Hill et al. shows that inhibition of proton cytosolic efflux in combination 
with up-regulation of oncogenic RAS expression is lethal for growing cells in 
Drosophila models [243]. These studies were also confirmed in cancer cells with 
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increased oncogene expression. Perhaps, a major break through could occur in the 
future with advancement in tumor imaging allowing for visualization of acidic regions 
of the tumor, which would make it easier to determine therapeutic approach.   
Conclusion & Future Directions 
Oncogenic KRAS drives metabolic response to acidosis 
In chapter 1 of this thesis I’ve described the somatic evolution of pancreatic 
ductal cells into PDAC and concluded that malignant transformation is a slow process 
limited by tissue-mediated growth inhibition and dependent on metabolic substrate 
uptake. To this end, malignant cells gain oncogenic KRAS mutation and develop loss 
of function in tumor suppressors TP53 and CDKN2A, which leads to unrestricted 
growth. The combination of intermittent hypoxia and oncogene expression in PDAC 
cells promotes growth and generation of an acidic TME. However, in order to sustain 
the cancer phenotype, PDAC cells must maintain alkaline pHi and acidic pHe pH 
dynamics, as deviation from this will be in detriment of growth and overall 
homeostasis of the cells. In order to regulate pH, cancer cells have developed active 
transport of protons into the extracellular space because increased pHe will impair 
passive transport of metabolic acids. This creates a paradox for cancer cells, as 
further growth will be detrimental for pH balance. Thus, I hypothesized that further 
tumor progression depends on pH regulation and metabolic reprograming to meet 
homeostatic demands. In chapter 2, I conducted several experiments to determine the 
metabolism of PDAC cells in chronic low ph. Here, I identified that chronic low ph 
reduced proliferation rate and the cancer cells rely more on oxidative metabolism 
instead of glycolysis for survival. This metabolic phenotype is supported by increased 
glutamine uptake. Glutamine is metabolized through the non-canonical glutamine 
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anapleurotic pathway, which allows the cells to produce pyruvate for decarboxylation 
reactions and ATP synthesis through ETC, as well as, NADPH that is useful for redox 
balance. This pathway shows metabolic reprogramming under chronic low ph that will 
favor biomass production, redox balance, and energy production. Most significantly, 
this pathway is possible because oncogenic KRAS increases the expression of GOT1 
and inhibits GLS1, which will lead to redirection of glutamine metabolism to the 
anapleurotic pathway. In non-acidosis conditions, the same pathway is essential for 
redox balance and growth, because NADPH production through anapleurotic 
glutamine metabolism compensates for lack of NADPH production from oxidative 
PPP. KRAS driven PDAC tumors are known to bypass oxidative PPP in order to 
accelerate rate of non-oxidative PPP to generate nucleic acids for cell replication. 
Therefore, oncogenic KRAS appears to be a critical regulator of cellular homeostasis 
in stress conditions by inducing metabolic reprogramming.  
Future Directions 
The observations by Grillo-Hill et al. confirm our hypothesis that up-regulated 
metabolic rate without means to regulate pH dynamics results in cell death. However, 
targeting pH regulation has been shown to be detrimental due to side effects of 
treatment, as all biological processes depend on pH regulation. Thus, one important 
avenue of research is to understand the signaling mechanisms allowing cancer cells 
to undergo metabolic reprogramming and membrane expression of pH regulating 
proteins. The pathways mediated by GPCRs and non-GPCR extracellular sensors 
have not been completely elucidated. Furthermore, known GPCR signaling is known 
cause inhibition of cytoskeleton remodeling not pH regulation per se. This is 
demonstrated by overexpression of GPR4 and OGR1 in cancer cells, which results in 
growth inhibition and invasiveness. This is likely because over-expression of pH 
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sensitive GPCRs will require less pHe disturbances to alert the cytosol of acidosis 
stress conditions and inhibit cytoskeleton remodeling [218]. While metabolic 
reprogramming and proton efflux would not be affected because the pH gradient is 
not changing; alternatively, the response can be induced by epigenetic changes as it 
has been demonstrated in HeLa cells that low pHi favors histone de-acetylation and 
alkaline pHi favors acetylation of histones [244]. Another interesting study to 
understand the evolution of pH dynamics in cancer is to evaluate somatic mutations, 
which occur randomly and may cause deleterious or advantageous alterations to gene 
function. However setting that gene product mutations aside, an interesting study 
regarding amino acid mutations landscape by Szpeech et al. shows that the 
predominant mutations in many solid tumors are that of arginine to histidine [245] 
[246]. These analyses predict that arginineàhistidine mutations occur in nearly 50% 
of the samples analyzed. This mutation is of particular interest for pHi regulation 
because of the role of histidine switches in actin remodeling control mechanisms due 
to acidic pHi response. Furthermore, increase in histidine amino acid residues will 
result in an increase buffer capacity since the pKa of histidine is around 6.5 and 
arginine is ~12, thus histidine will be able to titrate narrow pH changes [247]. 
Interestingly, p53 is one of the most studied molecules in cancer research because of 
its R273H mutation, which has been shown to be pH sensitive in a study by White et 
al. where it was demonstrated that arginineàhistidine had increased transcriptional 
activity in low pHi [246]. Thus, protonation of histidine will promote interaction with the 
phosphate backbone of DNA enabling transcription of p53 response genes. Further 
studies are required to elaborate more on the role of somatic mutations and their role in 
pHi regulation, as well as, the pH-induced posttranslational modifications and 
subsequent phenotypic alterations. Based on the observations made throughout this 
document, future perspectives in cancer therapy should take in consideration the 
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biologic significance of pH dynamics in order to determine better therapeutic 
approaches.   
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Chapter 3 Figures 
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Figure 1. Hypothetic metabolic-pH relationship in PDAC tumors. The metabolism of 
PDAC cells is defined by the oncogenic KRAS and oxygen availability. PDAC cells that 
are proximal to blood vessels can undergo rapid growth because pH dynamics are not 
affected due to rapid venting of protons and CO2. This is the classic Warburg effect seen 
during in vitro PDAC cell culture. Cells further away from blood vessels experience 
chronic low ph because proton venting is limited by growth of cells nearer to the 
vasculature. In addition, excess release of CO2 and CA expression will convert it to 
carbonic acid, which may generate more protons and bicarbonate to buffer pHi of cells 
undergoing acidosis stress. Cells that are the most distal from vasculature undergo 
hypoxia driven metabolic reprogramming that will further exacerbate acid load into the 
TME. Thus, cells closest to the hypoxic region will experience the most stress from TME 
acidosis.     
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